Stockwinners Market Radar for November 10, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EST Cathie Wood's ARK Investment bought 1.25M shares of Palantir on Wednesday

20:01 EST PHX Minerals announces mineral and royalty acquisitions in Haynesville - PHX Minerals announced three mineral and royalty acquisitions targeting the Haynesville play in East Texas and Louisiana. PHX has agreed to acquire approximately 827 net royalty acres for aggregate consideration of $5.2M in cash and stock from a private seller subject to customary closing adjustments. The purchase price consists of $520,000 in cash and 1,519,481 in PHX common stock issued directly to the seller of the assets.

19:24 EST Perimeter Solutions CFO buys 196.4K shares of common stock - In a regulatory filing, Perimeter Solutions disclosed that its CFO Barry Lederman bought 196.4K shares of common stock for $1.96M on November 9th.

19:06 EST Gilead says Phase 2B Trodelvy study meets primary ORR endpoint - Gilead Sciences reported that the Everest Medicines sponsored Phase 2b EVER-132-001 study of sacituzumab govitecan, marketed as Trodelvy in the U.S., met its primary endpoint of overall response rate in metastatic triple-negative breast cancer. EVER-132-001 is a single-arm, multi-center Phase 2b registrational study evaluating sacituzumab govitecan in 80 patients enrolled in China for the treatment of adults with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one for metastatic disease. The results demonstrated an ORR of 38.8% as evaluated by an Independent Review Committee. The safety profile of sacituzumab govitecan was similar to that reported in prior studies, and no new safety signals were identified. The primary endpoint measured ORR according to RECIST v1.1 by an Independent Review Committee. The results were consistent with results demonstrated in the global Phase 3 ASCENT study. Gilead and Everest Medicines are engaged in a joint partnership for the development and commercialization of sacituzumab govitecan in Asia. "These topline results confirm that sacituzumab govitecan has the potential to help change the treatment outlook for people in China living with mTNBC," said Yang Shi, Chief Medical Officer for Oncology at Everest Medicines. "These data, along with the benefit seen in the global ASCENT study, support its potential as a novel treatment for patients who currently have extremely limited options."

18:40 EST Tesla CEO exercises 2,154,572 options at $6.24 - According to a regulatory filing, Tesla CEO Elon Musk exercised 2,154,572 options at $6.24 per share on November 8. According to Bloomberg, Musk also sold tens of thousands of common shares in multiple transactions to satisfy taxes from the options.

18:31 EST Pool Corp. to acquire Porpoise Pool & Patio, terms not disclosed - Pool Corporation announced that it has signed a definitive agreement to acquire Largo, Florida-based Porpoise Pool & Patio, Inc., including its main operating subsidiaries, Sun Wholesale Supply, Inc. and Pinch A Penny, Inc. Sun Wholesale Supply, Inc. is a wholesale distributor of swimming pool and outdoor-living products, including a specialty chemical packaging operation, selling primarily to Pinch A Penny franchisees. Pinch A Penny, Inc. is the largest franchisor of pool and outdoor living-related specialty retail stores in the United States with approximately 260 independently owned and operated franchised stores in Florida, Texas, Louisiana, Alabama and Georgia and brings substantial opportunities for expansion. "We are excited about combining our industry-leading distribution capabilities with Porpoise Pool & Patio's well-established customer base, world-class chemical packaging operation, history of operational excellence, and strong growth-oriented Pinch A Penny brand. Since its founding over 45 years ago, Pinch A Penny has steadily grown and developed into a leading franchisor of swimming pool specialty retail stores and one of the highest-rated U.S. retail store franchise networks," said Peter D. Arvan, POOLCORP President and CEO. "The addition of the Pinch A Penny franchise network to POOLCORP's North American distribution business brings substantial growth and operating synergies for both existing independent retail customers and independent franchisees." The parties anticipate completing the transaction by December 31, 2021, subject to the satisfaction of regulatory and other customary closing conditions.

18:13 EST MediciNova presents new data regarding MN-166 at CURE OM meeting - MediciNova announced that Grazia Ambrosini, PhD, an associate research scientist at Columbia University Vagelos College of Physicians and Surgeons, presented data regarding MN-166 in a uveal melanoma model study at the 10th Annual CURE OM Global Science Meeting held online as a part of the Society for Melanoma Research International Congress on October 28, 2021. This study was a collaborative effort between MediciNova and Dr. Ambrosini, Richard D. Carvajal, MD, associate professor of medicine at Columbia Vagelos College of Physicians and Surgeons and co-director of the Precision Oncology and Systems Biology research program at the Herbert Irving Comprehensive Cancer Center, and Gary Schwartz, MD, professor of oncology at Vagelos College of Physicians and Surgeons, Division Chief of Hematology/Oncology at Columbia University Irving Medical Center, and Deputy Director at the HICCC. Dr. Carvajal commented, "We are excited about the preclinical data generated with the MIF inhibitor MN-166 in this uveal melanoma model study. Uveal melanoma is the most common primary intraocular malignancy and nearly half of patients ultimately will develop metastasis. Metastases are most frequently localized to the liver and associated with a poor prognosis. Currently there are no effective preventive treatments for uveal melanoma. Previously, our group identified MIF as a critical mediator of metastatic spread. In our new study, MN-166 treatment prevented remote metastasis in the orthotopic uveal melanoma model."

17:50 EST GeoPark renews buyback program for up to 10% of shares outstanding - GeoPark Board of Directors has approved the renewal of the repurchase program for up to 10% of shares outstanding or approximately 6,074,000 shares, expiring on November 10, 2022.

17:33 EST Beyond Meat CFO says Q4 to remain impacted by operational challenges of Q3 - Says: "The following factors worth highlighting are embedded in Q4 guidance. First, we anticipate a moderation in year-over-year growth across all channels due to the fact that this year, our fourth quarter contains 5 fewer shipping days compared to the fourth quarter of 2020. Second, we expect our fourth quarter results to be impacted by knock-on effects from the operational challenges in Q3. Although we expect to be fully recovered by the end of this month, these issues presented some headwinds early in the quarter. Third, in both U.S. and international Foodservice channels, ongoing labor challenges as well as general caution based on code-related uncertainty are also expected to have a dampening effect on the net levels. Finally, we expect the moderation of sequential growth due to accelerated orders in the third quarter of 2021 that would otherwise have been expected to materialize in the fourth quarter." Comments taken from Q3 earnings conference call.

17:19 EST Arbutus Biopharma announces new AB-729 data at AASLD - Arbutus Biopharma announced new AB-729 safety and efficacy data, as well as long-term data from HBV patients following discontinuation of treatment with AB-729. The data are from part 3 of the company's ongoing Phase 1a/1b clinical trial with 60 mg or 90 mg of AB-729 dosed every four, eight or 12 weeks. The data will be presented at AASLD. Data from the poster presentation include long-term follow-up data for patients in cohort E and cohort F who had been off AB-729 treatment for six months. Suppression of HBsAg to levels less than100 IU/mL were maintained up to 24 weeks off-treatment in 3 of 7 patients in cohort E and 1 of 3 patients with available data in cohort F. Patients who remain below this clinically relevant threshold for six months after stopping AB-729 treatment could consider discontinuing their nucleos(t)ide analogue therapy to assess the potential for functional cure. Also included in the poster presentation are data showing that robust mean declines in HBsAg were sustained with repeat dosing of AB-729 up to 48 weeks, with no statistically significant differences observed to date between the 60 mg and 90 mg dose and/or dosing intervals. Repeat dosing of both the 60 mg and 90 mg doses of AB-729 continues to be generally safe and well- tolerated. There were no treatment related serious adverse events or discontinuations. The most common treatment emergent adverse events were injection site related of which all were grade one and did not appear to be dose or interval dependent. ALT and AST elevations were asymptomatic and not considered adverse events by the study investigators. A total of 34 patients were enrolled in cohorts E, F, G, I, and J, all of which met the eligibility criteria to participate in the treatment extension and 33 of which agreed to continue treatment. HBV DNA negative patients on stable NA therapy were enrolled in part 3 of this trial to receive 60 mg of AB-729 every 4 weeks or 8 weeks or 90 mg of AB-729 every 8 weeks or 12 weeks. HBV DNA positive patients received 90 mg of AB-729 every 8 weeks in addition to current standard of care treatment, tenofovir disoproxil fumarate. HBV DNA negative/HBeAg positive patients are continuing to be dosed with 90 mg of AB-729 every 8 weeks.

17:14 EST Cooper Companies to acquire Generate Life Sciences for $1.6B, sees accretion - CooperCompanies announced that it has signed a definitive purchase agreement to acquire Generate Life Sciences, a privately held leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage. Cooper will pay approximately $1.6B to acquire Generate Life Sciences. The transaction is anticipated to close in Cooper's Q1 and is subject to customary closing conditions, including regulatory approval. Generate Life Sciences reported approximately $250M in trailing twelve-month revenues as of September 30. Excluding one-time charges and deal-related amortization, the acquisition is expected to be accretive to Cooper's non-GAAP earnings per share by approximately 30c in the first year after closing.

17:10 EST Opendoor Technologies jumps 15% to $22.78 after Q3 results beat estimates - The company's Q4 revenue guidance also topped estimates.

17:04 EST EnerSys names Andrea Funk as CFO, effective April 1, 2022

17:03 EST EnerSys announces new $100M stock repurchase authorization - EnerSys announced that its Board of Directors has established a new $100M stock repurchase authorization with no expiration date. The authorized repurchases will be made from time to time in either the open market or through privately negotiated transactions, the company said in a statement.

17:02 EST Sight Sciences reports FDA authorization for PRECISION trial in POAG - Sight Sciences announced that the FDA has granted an Investigational Device Exemption authorizing the Company to conduct a clinical study to assess the safety and effectiveness of a new, higher volume, investigational OMNI device to perform canal viscodilation alone to lower intraocular pressure in adults with primary open-angle glaucoma. The PRECISION clinical trial is designed as a three-armed randomized controlled trial, which the company believes will be the first of its kind and represents the largest MIGS clinical trial ever initiated, based on total number of patients receiving MIGS interventions in conjunction with cataract surgery. The devices that will be evaluated in the study are the higher volume OMNI and the iStent Inject Canal Implant. In the three arms of the study, patients will receive one of the following treatments in conjunction with cataract surgery: (1) ab interno canaloplasty alone using higher volume OMNI; (2) sequential canaloplasty followed by trabeculotomy using higher volume OMNI; or (3) implantation of two trabecular microbypass canal implants using iStent Inject. The PRECISION study is intended to evaluate for regulatory purposes the safety and efficacy of higher volume OMNI for use in canaloplasty without sequential trabeculotomy for IOP and medication reduction in adult patients with POAG.

16:54 EST Beyond Meat falls over 18% at $77.40 after wider than expected Q3 loss

16:48 EST Tattooed Chef reschedules Q3 earnings annoucnement - Tattooed Chef announced it will reschedule its third quarter 2021 earnings release and conference call previously scheduled for November 10, 2021. The delay is a result of additional time required to finalize the Company's financial statements, and the Company will make a further announcement regarding the timing of the release and conference call as soon as practicable.

16:43 EST Lockheed, Keysight test 5G solutions for aerospace, defense communications - Lockheed Martin (LMT) and Keysight Technologies (KEYS) announced a collaboration to advance 5G in support of mission-critical communications for aerospace and defense applications. The companies are actively collaborating on a 5G.MIL testbed that Lockheed Martin teams will use to advance 5G capabilities for multiple applications. "Lockheed Martin is leveraging expertise in the commercial sector to scale, adapt and integrate 5G technology rapidly and affordably across mission-critical operations across land, sea, air, space and cyber domains," said Dan Rice, vice president for 5G.MIL Programs at Lockheed Martin. "Keysight's end-to-end 5G test platforms, widely used commercially, provide an opportunity to develop customized solutions that meet the stringent requirements of the defense industry."

16:42 EST AppLovin reports Q3 adjusted EBITDA $191M, up 126% from last year

16:38 EST Affirm jumps 21% to $162.55 after results, expanded Amazon relationship

16:36 EST Red Robin sees mid-single-digit commodity and wage inflation - The Company currently expects the following for FY21: Mid-single digit commodity and wage inflation; Selling, general and administrative costs between $120M and $130M; Capital expenditures of $45M to $55M, including continued investment in maintaining our restaurants and systems capital, Donatos(R) expansion to approximately 120 restaurants, including approximately 40 restaurants in our fourth fiscal quarter, digital guest and operational technology solutions, and off-premises execution enhancements.

16:34 EST Sigilon Therapeutics announces upcoming milestones - Sigilon expects to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021. The Company expects to provide up to 12 months of follow-up data for three patients from the Phase 1/2 safety and dose-ranging study of SIG-001 in severe to moderate-severe hemophilia A in the fourth quarter of 2021.

16:33 EST Leidos awarded three-year contract by the MOD worth up to GBP70M - Leidos was recently awarded a three-year (with optional 4th year) contract by the MOD (worth up to GBP70M with all options) to deliver GEOINT capability in support of the UK's National Centre for Geospatial Intelligence as part of the PICASSO programme.

16:29 EST Guild Holdings declares special cash dividend of $1.00 per share - The Board of Directors of Guild declared a special cash dividend of $1.00 per share on its Class A and Class B common stock. The $1.00 per share dividend will be paid on or about December 8, 2021 to stockholders of record on November 22, 2021.

16:24 EST WalkMe enters alliance agreement with Deloitte - WalkMe announced it has entered into an alliance agreement with Deloitte, a global company in Human Capital and Business Transformation Consulting. Deloitte is investing in a dedicated team in the U.S. to provide technology adoption solutions via its newly-created Digital Adoption Services business. Developed in conjunction with WalkMe, clients can leverage these services to realize the rapid results that digital transformation strategies can deliver.

16:22 EST GI Partners to sell Generate Life Sciences to CooperCompanies - GI Partners announced the signing of a definitive agreement to sell Generate Life Sciences, a life sciences platform that provides reproductive and newborn stem cell services, to CooperCompanies. The transaction is subject to customary closing conditions and is expected to be completed in December. Terms were not disclosed.

16:14 EST RLI Corp. names Kliethermes CEO, Klobnak COO - RLI Corp. announced that the RLI Board of Directors has appointed Craig W. Kliethermes as President and Chief Executive Officer (CEO) and Jennifer L. Klobnak as Chief Operating Officer (COO), effective January 1, 2022. These leadership changes will coincide with the planned retirement of current company Chairman & CEO Jonathan E. Michael at the end of 2021. Kliethermes has served as President and COO since 2016. Previously, he served as Senior Vice President, Risk Services since 2013. Kliethermes joined RLI in 2006 and has 36 years of insurance industry experience. Prior to joining RLI, he served in various actuarial and leadership roles with Lockton Companies, GE Insurance/Employers Reinsurance and John Deere Insurance Company. Klobnak has served as Senior Vice President, Operations since 2016. Previously, she served as Senior Vice President, Risk Services since 2014. Klobnak joined RLI in 2000 and has 21 years of insurance industry experience. Prior to joining RLI, she served in an audit role with PwC.

16:13 EST Dutch Bros reports Q3 same shop sales up 7.3% - System same shop sales grew 7.3% in the third quarter and 10.7% on a two-year basis. Company-operated same shop sales grew 4.7% in the third quarter and 10.1% on a two-year basis. System same shop sales grew 7.3% in the third quarter and 10.7% on a two-year basis. Company-operated same shop sales grew 4.7% in the third quarter and 10.1% on a two-year basis.

16:12 EST Aeva Technologies selected by Plus in volume production of autonomous trucks - Plus "has selected Aeva to supply automotive grade long-range 4D LiDAR for the production of driver-in and fully autonomous trucks powered by the PlusDrive system. Aeva's high performance LiDAR will help Plus autonomous trucks sense their environment clearly at long ranges, shorten response time in safety-critical situations, and address edge cases leveraging Aeva's proprietary instant velocity data."

16:09 EST ContextLogic CEO Piotr Szulczewski to step down - ContextLogic announced that Piotr Szulczewski will be stepping down as Chief Executive Officer. He will remain on the Company's board of directors. To ensure an orderly transition, Mr. Szulczewski will remain CEO until either a successor is appointed by the Company's board of directors, or no later than February 1, 2022. The Company has engaged an executive search firm to assist in recruiting a new CEO. "As Wish's Founder and CEO for more than 10 years, Piotr has played an instrumental role in creating a global, publicly-traded, billion-dollar ecommerce marketplace that millions of shoppers use every day. He has laid the groundwork for Wish to continue to grow and thrive and will leave the business in the capable hands of our new, highly talented and invigorated leadership team," said Tanzeen Syed, Lead Independent Director, Wish. "On behalf of the Board of Directors and the entire team at Wish, I want to express my sincerest gratitude to Piotr for his contributions to the company. We look forward to him continuing to guide Wish as a member of our board of directors as we enter our next stage of growth."

16:06 EST Disney reports 118.1M Disney+ paid subscribers as of October 2 - Reports Disney+ paid subscribers of 118.1M, up from 73.7M last year. Reports ESPN+ paid subscribers 17.1M vs. 10.3M last year. Reports total Hulu paid subscribers 43.8M vs. 36.6M last year.

16:03 EST Hims & Hers unveils mobile platform for over 500,000 subscription members - Hims & Hers Health unveiled its plans to provide more complete, holistic and personalized care experiences with the launch of the Hims & Hers mobile app. The company intends to begin rolling out the app to its over 500,000 subscription members in the coming weeks. "Today marks one of the most important announcements in our Company's history as we continue toward our goal of fundamentally reshaping what it means to access and experience great modern healthcare," said CEO and Co-Founder of Hims & Hers Andrew Dudum. "Imagine a world where beginning the path towards better health is as easy as pushing "Play" on a guided and integrated Program. A Program led by inspiring and passionate coaches, supported by leading medical specialists in the country, that brings together streamlined education, original content, community support, access to treatment and oversight. Imagine a world where the concept of scheduling an appointment, coordinating a visit, or asking about even the smallest health concern is as simple as texting your Concierge."

15:44 EST DOJ requires divestitures in Lactalis deal for Kraft Heinz U.S. cheese unit - The Department of Justice announced that it will require B.S.A. S.A., or "Lactalis," and Kraft Heinz to divest Kraft Heinz's Athenos and Polly-O businesses in order to proceed with Lactalis' proposed acquisition of Kraft Heinz's natural cheese business in the United States. The Justice Department's Antitrust Division filed a civil antitrust lawsuit today in the U.S. District Court for the District of Columbia to block the proposed transaction. At the same time, the department filed a proposed settlement that, if approved by the court, would resolve the competitive harm alleged in the lawsuit. Reference Link

14:58 EST Assurant raises quarterly dividend 3% to 68c per share - Assurant announced that its Board of Directors approved a quarterly dividend increase of 2c to 68c per share of common stock. The dividend will be payable on December 20, 2021, to stockholders of record as of the close of business on November 29, 2021. "Our disciplined capital management, driven by robust cash generation in our market-leading lifestyle and housing businesses, has always been a key differentiator for Assurant," said Alan Colberg, CEO, Assurant. "That has allowed us flexibility to invest in our growth businesses and return capital to shareholders, including the recent completion of our three-year $1.35 billion capital return objective. Looking ahead, we are increasing the dividend 3 percent, marking the 17th consecutive dividend raise since our initial public offering and reaffirming the strength and ongoing visibility of Assurant's future cash flow generation."

14:46 EST Valve delays Steam Deck launch to February 2022 - Valve said that the launch of Steam Deck, its upcoming handheld gaming device, will be delayed by two months. "We're sorry about this-we did our best to work around the global supply chain issues, but due to material shortages, components aren't reaching our manufacturing facilities in time for us to meet our initial launch dates," the company said. "Based on our updated build estimates, Steam Deck will start shipping to customers February 2022. This will be the new start date of the reservation queue-all reservation holders keep their place in line but dates will shift back accordingly. Reservation date estimates will be updated shortly after this announcement. Again, we're sorry we won't be able to make our original ship date. We'll continue working to improve reservation dates based on the new timeline, and will keep folks updated as we go." Companies in the video game hardware space include Nintendo (NTDOY), Sony (SONY), and Microsoft (MSFT). Reference Link

14:11 EST Biogen, Eisai present updates on lecanemab Phase 2b 201, OLE studies - Eisai (ESALY) and Biogen (BIIB) announced results of new clinical, biomarker and safety assessments of brain amyloid reduction and five-year clinical status of people living with early Alzheimer's disease from the lecanemab Phase 2b 201 and the open-label extension, or OLE, studies. An OLE with 10 mg/kg IV biweekly lecanemab dosing was implemented after analysis of the 18-month, core phase with an intervening off-treatment period ranging from 9-59 months. The OLE phase evaluated the effect of lecanemab on amyloid PET over 12 months of treatment, including earlier time points than in the core phase. This study design provided the opportunity to explore the biomarker and clinical effects of stopping and restarting lecanemab across five years of disease trajectory. The updated assessment of the OLE phase showed that treatment with lecanemab resulted in reduction of brain amyloid levels in as early as 3 months based on OLE data and robust clearance of amyloid plaque with more than 80% of participants achieving amyloid negative status by 12-18 months of treatment as measured by PET. These results are consistent with core phase results. The 201 study core data suggested that clinical efficacy is correlated with amyloid reduction at both the population and subject levels. Amyloid PET levels were significantly reduced by quantitative assessment in newly treated OLE subjects in as early as 3 months after initiation of treatment. Additionally, the core data suggested that clinical efficacy is correlated with plasma Abeta at both the population and subject levels. The clinical treatment difference in study participants between lecanemab treatment and placebo at the end of core period, is maintained after discontinued dosing over the 24-month Gap period. The reduction of clinical decline of participants receiving the highest dose of lecanemab relative to placebo at the end of the 18-month, core period showed a difference of 0.05 in ADCOMS. This treatment difference of 0.10 in subjects who entered OLE was maintained while off-treatment during the gap period up to the beginning of the OLE. Similar findings were observed for CDR-SB and ADAS-Cog, although both groups continued to progress. This pattern of sustained treatment effect after stopping lecanemab, reflected in biomarkers as well amyloid PET, plasma Abeta42/40 and ptau181 is consistent with a disease-modifying effect. New results were also presented for two new blood tests that were measured in the Phase 2b and OLE studies: Plasma Abeta 42/40 ratio and Plasma p-tau181. Plasma Abeta 42/40 ratio changes suggested an inverse correlation with amyloid PET changes. Both amyloid PET and blood Abeta show correlation with ADCOMS at the population and individual levels in the core phase. Monitoring of treatment effects using plasma biomarkers may allow simple dose modification following robust amyloid removal. Consistent with the safety findings in the core period, lecanemab was well-tolerated with less than10% incidence of ARIA-E at 10-mg/kg biweekly in the Core and OLE. The incidence of symptomatic ARIA-E was less than2% in Core and OLE. This safety profile enables lecanemab to be initiated at the therapeutic dose without titration.

13:23 EST Apple loses second appeal over Qualcomm patent decisions - Apple (AAPL) appealed four decisions of the Patent Trial and Appeal Board to the U.S. Court of Appeals for the Federal Court determining that claims of patents owned by Qualcomm (QCOM) weren't proven unpatentable. The appeals court wrote: This is the second such dispute to reach us since these parties settled all their patent infringement litigation worldwide and entered a global patent license agreement. In the first, we dismissed because Apple lacked Article III standing before this court. Apple Inc. v. Qualcomm Inc., 992 F.3d 1378, 1385. Along the way, Apple I foresaw that the standing issue 'impacts . . . other appeals.' Id. at 1382. Confronted here with identical operative facts, we do no more than follow in the wake of Apple I. We dismiss."

13:16 EST Uber sued by Justice Department over charging people with disabilities - The Justice Department filed a lawsuit against Uber Technologies for charging "wait time" fees to passengers who, because of disability, need more time to enter a car. "Uber's policies and practices of charging wait time fees based on disability have harmed many passengers and potential passengers with disabilities throughout the country," the DOJ said in a statement. The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges that Uber violated Title III of the Americans with Disabilities Act , which prohibits discrimination by private transportation companies. The lawsuit seeks relief from the court, including ordering Uber to stop discriminating against individuals with disabilities. Additionally, the department asks the court to order Uber to "modify its wait time fee policy to comply with the ADA; train its staff and drivers on the ADA; pay money damages to people subjected to the illegal wait time fees; and pay a civil penalty to vindicate the public's interest in eliminating disability discrimination." Reference Link

12:16 EST YouTube removes dislike count on all videos - In a company blog post, the YouTube Team said, "At YouTube, we strive to be a place where creators of all sizes and backgrounds can find and share their voice. To ensure that YouTube promotes respectful interactions between viewers and creators, we introduced several features and policies to improve their experience. And earlier this year, we experimented with the dislike button to see whether or not changes could help better protect our creators from harassment, and reduce dislike attacks - where people work to drive up the number of dislikes on a creator's videos. As part of this experiment, viewers could still see and use the dislike button. But because the count was not visible to them, we found that they were less likely to target a video's dislike button to drive up the count. In short, our experiment data showed a reduction in dislike attacking behavior. We also heard directly from smaller creators and those just getting started that they are unfairly targeted by this behavior - and our experiment confirmed that this does occur at a higher proportion on smaller channels. Based on what we learned, we're making the dislike counts private across YouTube, but the dislike button is not going away. This change will start gradually rolling out today." Reference Link

12:03 EST Toast falls -14.7% - Toast is down -14.7%, or -$8.90 to $51.85.

12:03 EST FuboTV falls -17.9% - FuboTV is down -17.9%, or -$5.94 to $27.19.

12:01 EST Xbox boss says 'Forza Horizon 5' has over 4.5M players just days after launch - Xbox boss Phil Spencer said in a tweet yesterday that the latest Xbox-exclusive title "Forza Horizon 5" has over 4.5M players so far across PC, cloud, and console. The game has experienced the largest launch day for an Xbox Game Studios title, with its peak concurrent player counter three times as high as the peak for "Forza Horizon 4." "Forza Horizon 5" launched for early access buyers on November 5 and for everyone else on November 9, and the game was available day one for Xbox Game Pass subscribers, The Fly notes. Reference Link

12:00 EST ATI Physical Therapy rises 39.1% - ATI Physical Therapy is up 39.1%, or $1.16 to $4.13.

11:55 EST Charlotte's Web introduces CBG, CBN oral sprays for stress, sleep support - Charlotte's Web Holdings has added new oral sprays to the Company's e-commerce website. The company said, "The Charlotte's Web Calm Spray and Sleep Spray with CBG and CBN features a format that delivers the hemp extract in a consistent measure. Developed to help consumers manage their everyday stress or support a healthy sleep cycle, these are the Company's first products developed around the minor cannabinoids cannabigerol and cannabinol. Both sprays contain broad spectrum proprietary hemp extract with naturally occurring CBD and other beneficial botanicals for a THC-Free on-the-go option just in time for holiday travel." Charlotte's Web Calm Spray is lemon flavored and comes in a 10mL size, approximately 100 sprays: $49.99 SRP. Charlotte's Web Sleep Spray is mint flavored and comes in a 10mL size, approximately 100 sprays: $49.99 SRP. The new oral sprays launched on the Company's e-commerce website as an exclusive, limited-time offer ahead of a nationwide launch with retailers in 2022.

11:43 EST Ford, Purdue patent fast-charging station cable - Ford and Purdue University researchers have "taken an important early step to make recharging EVs simple and time saving," the automaker announced. Ford said: "Through a research alliance, researchers from both groups are working to develop a new, patent-pending charging station cable that could combine with in-development vehicle charging technology, making it even easier for people to transition to EVs with seamless re-charging." Reference Link

11:36 EST General Motors names Fred Killeen VP of Global Information Technology and CIO

11:35 EST General Motors restructures IT function into two groups

11:17 EST Redwire down 14% after rescheduling Q3 earnings announcement - Shares of Redwire are down $1.70, or 14%, to $10.21 in Wednesday morning trading after the company announced last night that it would reschedule its earnings announcement for the third quarter ended September 30, which had been previously scheduled for Wednesday, November 10. "The company will share details for the revised scheduling, including the timing for the earnings conference call and webcast, once the new date has been set," Redwire stated.

11:08 EST Shift4 announces five-year strategic partnership with SpaceX Starlink - Shift4 Payments in investor day presentation slides announced a five-year global strategic partnership with SpaceX Starlink. Shift4 said its 120-day plan is to convert domestic payment volume to Shift4 acquiring. "SpaceX Starlink is a cornerstone, global client opening up opportunity throughout the globe by servicing the business globally, Shift4's TAM expands in all the verticals we serve," the company said. It estimates long term SpaceX Starlink only subscription payments at $100B. Shift4 Payments also highlighted a $500B-plus total address market in satellite based consumer broadband plus internet services by 2040. This "opens up massive pool of global commerce opportunities," the company noted. Shares of Shift4 Payments are up 16%, or $9.24, to $68.00 in morning trading.

11:02 EST Renewable Energy announces strategic partnership with Booster - Booster, which identifies itself as "the tech-enabled energy delivery service," and Renewable Energy Group announced what they say is "a first-of-its-kind partnership" to provide mobile delivery of renewable diesel, biodiesel and blended fuels to fleets. The service started in California in August and has the potential to grow nationally, the companies stated in a press release. As part of the partnership, REG will be an exclusive supplier of bio-based diesel to Booster, and has become an investor in the company. Booster will also be an exclusive mobile fueler to REG and will partner with REG to explore expansion opportunities together. The REG / Booster collaboration will initially focus on servicing fleet customers in California, starting with the San Francisco Bay Area and Orange County, with additional markets to follow. "This collaboration is a perfect match for us, bringing together two innovative, sustainable solutions and building on our downstream strategy to reach customers and provide a first-class experience. The energy transition is happening and this is the right place and right time for customers to adopt bio-based diesel and immediately reduce emissions in an easy and efficient manner. Our investment in Booster solidifies our commitment to enabling consumers with the ability to access clean fuel choices," said REG Senior Vice President, Sales & Marketing, Bob Kenyon.

10:26 EST Wejo, Virtuoso Acquisition in purchase pact with Apollo for up to $75M

10:08 EST Blackstone appoints Jean Rogers as global head of ESG - Blackstone announced that Dr. Jean Rogers, Founder and Former CEO of the Sustainability Accounting Standards Board, will be joining the firm in January 2022 as its Global Head of Environmental, Social and Governance. Dr. Rogers will oversee Blackstone's corporate ESG team, leading strategy, integration, reporting and engagement. She will partner closely with our business unit heads of ESG, operational and asset management teams and other functional groups across the firm to ensure a highly integrated and coordinated approach.

10:02 EST Apple introduces 'Apple Business Essentials' service, available today in beta - Apple has announced "Apple Business Essentials," which the company calls "an all-new service that brings together device management, 24/7 Apple Support, and iCloud storage into flexible subscription plans for small businesses with up to 500 employees." The company also unveiled a new Apple Business Essentials app that enables employees to install apps for work and request support, Apple stated. A set of three Apple Business Essentials plans "enable businesses to cover every employee and device in their organization," Apple said. Plans can be customized to support each user with up to three devices and up to 2TB of secure storage in iCloud, starting at $2.99 per month, with optional AppleCare+ for Apple Business Essentials. Apple Business Essentials is available as a free beta starting today in the US. The service will be fully available in the spring of 2022.

10:01 EST Digimarc names Ken Sickles as Chief Product Officer - Digimarc announced it has appointed Ken Sickles as Chief Product Officer, a key member of the leadership team. Reporting to the CEO, Riley McCormack, Sickles will help develop, deliver and support Digimarc's world-class global technology platform that advances the reach and effectiveness of automatic identification of media across multiple industries, while also supporting product and engineering teams and go-to-market strategies. Sickles joins Digimarc from ThinkTank, where he was Chief Technology Officer/Chief Product Officer from 2017 through 2021 and was a key contributor in the acquisition of the company by Accenture in May 2021.

10:00 EST FuboTV falls -16.2% - FuboTV is down -16.2%, or -$5.37 to $27.76.

10:00 EST Shift4 Payments rises 19.8% - Shift4 Payments is up 19.8%, or $11.65 to $70.37.

10:00 EST RingCentral rises 26.0% - RingCentral is up 26.0%, or $60.86 to $294.50.

09:58 EST PureTech granted orphan status for pancreatic cancer treatment - The FDA granted PureTech Health orphan status for its monoclonal antibody for the treatment of pancreatic cancer. Reference Link

09:55 EST Germany recommends Pfizer vaccine over Moderna for young, pregnant - Germany's vaccine commission recommended that people under 30 and pregnant women should get the Pfizer (PFE) and BioNTech (BNTX) Covid shot rather than one from Moderna (MRNA). Rare heart-inflammation side effects appear more common with Moderna's shot in younger patients, the commission said in a statement. Reference Link

09:51 EST WWE enters multi-year partnership with National Medal of Honor Museum Foundation - The National Medal of Honor Museum Foundation announced an official multi-year partnership with WWE. As part of the partnership, WWE will help the Museum compellingly tell the stories of the recipients of the nation's highest award for valor in combat, the Medal of Honorm while supporting the overall mission to build a Museum in Arlington, TX, and a Monument in Washington, DC, in recognition of the values the Medal represents: courage and sacrifice, commitment and integrity, citizenship and patriotism. The partnership kicks off at the special WrestleMania On-Sale Party at AT&T Stadium, home of the Dallas Cowboys. Medal of Honor recipient and NMOHMF board member Major General Pat Brady will be honored by WWE at the event. In addition, for every WrestleMania souvenir ticket issued at the party, $1 will go to support NMOHMF. The partnership will also be featured on WWE programming, including during WWE's Tribute to the Troops special airing this Sunday, November 14 on FOX, where WWE will spotlight legendary Medal of Honor recipient Woody Williams - the last living recipient from World War II - in partnership with NMOHMF.

09:48 EST Hyliion Holdings falls -13.3% - Hyliion Holdings is down -13.3%, or -$1.17 to $7.64.

09:47 EST Doximity falls -14.7% - Doximity is down -14.7%, or -$11.25 to $65.26.

09:47 EST Shift4 Payments rises 23.2% - Shift4 Payments is up 23.2%, or $13.64 to $72.36.

09:41 EST BioSig Technologies installs PURE EP System in another hospital in Texas - BioSig Technologies announced that it is installing a PURE EP System for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, TX. This is the Company's 17th installation and its fifth in Texas. "Heart disease and stroke remain at the top of leading causes of disability in Texas1, and we are committed to working with more physicians in this state as they strive to reduce the societal burden caused by heart disease. Medical City Heart provides specialized care for all types of cardiac rhythm disorders, and we are looking forward to contributing our technological and clinical know-how in this new collaboration," commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies. To date, over 71 physicians have completed over 1600 patient cases with the PURE EP System. The Company is in a focused commercial launch of the PURE EP System in the Northeast, Texas, and Florida. The technology is regularly used in some of Texas's highest-ranked hospitals, including St. David's Medical Center, Houston Methodist Hospital, and Medical City North Hills.

09:39 EST EVmo launches integrated gig delivery technology platform - EVmo announced the launch of a crowd-sourced delivery application that will provide renters on the EVmo platform with exclusive access to same day delivery job opportunities for items such as hot food, e-commerce packages, groceries, and on-demand fulfillment of consignments requiring urgent delivery. "This innovative application provides an intuitive approach to order management and delivery optimization with real-time updates to retailers and delivery recipients at the completion of each delivery," said Stephen Sanchez, CEO of EVmo. "The advanced algorithm underpinning the gig delivery application transforms complex logistical challenges associated with multiple deliveries into intuitive navigational assistance. Using the technology, EVmo renters will have the ability to optimize selected orders across multiple retailers and multiple delivery destinations, with the application providing the most efficient delivery route, improving the overall customer and renter experience." Sanchez continued, "We are very proud of this groundbreaking innovation and how it allows us to further do our part in creating income opportunities for our renters. Empowering gig workers with the tools to participate in the rapidly expanding gig economy is core to our corporate DNA. We believe that this is a game changer in the industry, and it fully differentiates us from others in the rideshare space."

09:37 EST Verano Holdings to acquire Caring Nature, Connecticut Pharmaceutical Solutions - Verano Holdings announced it has entered into multiple agreements to acquire all of the issued and outstanding equity interests of Caring Nature, LLC and Connecticut Pharmaceutical Solutions, Inc., along with the closing of its acquisition of Willow Brook Wellness, LLC. Caring Nature owns an active dispensary in Waterbury, CT; Connecticut Pharmaceutical Solutions owns an operating cultivation and production facility in Rocky Hill, CT; and Willow Brook Wellness holds an active dispensary in Meriden, CT. Collectively, these acquisitions expand Verano's presence on the East Coast with the addition of vertically integrated operations in the attractive Connecticut market. The transaction to acquire 100% of the equity interests of Willow Brook Wellness, LLC, includes one active dispensary in Meriden, Connecticut. The agreement was signed on September 13, 2021, and closed on October 25, 2021. The transaction to acquire 100% of the equity interests of Caring Nature, LLC, includes one active dispensary in Waterbury, Connecticut. The agreement was signed on November 10, 2021. The transaction to acquire 100% of the equity interests in Connecticut Pharmaceutical Solutions, Inc., includes an active, 216,532 sq. ft. state-of-the-art cultivation and production facility in Rocky Hill, Connecticut. Aggregate proceeds for the transaction include US$113,250,000 in subordinate voting shares of the Company upon the consummation of the transaction, US$18,500,000 in subordinate voting shares of the Company upon the first adult-use sale of cannabis in Connecticut, and additional subordinate voting shares based on achieving 2021 EBITDA performance milestones. The agreement was signed on November 10, 2021. Connecticut Pharmaceutical Solutions, Inc. is a portfolio company of Tuatara Capital, L.P. Closing of the Caring Nature, LLC and Connecticut Pharmaceutical Solutions, Inc. transactions are each subject to customary conditions, contingencies, and approvals, including regulatory approval.

09:36 EST Steppe Gold announces $65M in project finance, working capital debt facility - Steppe Gold is extremely pleased to announce that it has reached agreement for up to $65m in debt capital to fast track its phase two construction of the ATO Gold Mine. Of the total $65m in Loans, MNT 170 billion or approximately US$59.7m has been funded through the Gold-2 National Program, facilitated through the Central Bank of Mongolia. The 2021 Gold-2 Loan proceeds were advanced during the third quarter to Steppe Gold by the Trade and Development Bank of Mongolia. The 2021 Gold-2 Loan is a special purpose covenant-light loan, with a three-year term at 9% interest and full prepayment rights without penalty. All interest amounts are paid monthly. Draw down of the loan proceeds will commence on completion of registration of security, expected later this month. Further the Company has reached agreement for an additional US$5m for allocation to working capital to be funded directly from TDBM in the form of a prepaid gold sales loan. The TDBM Gold Loan will be repaid over a period of 12 months based on gold sales, with repayments in cash equivalent at MongolBank gold prices. With its Phase 2 Expansion headline numbers announced on October 27 and construction already commenced on the expanded crushing circuit the Company will now allocate the proceeds of the Gold-2 Loan to fast track the construction of the Phase 2 Expansion Project.

09:30 EST Heritage Commerce hires David Casassa as SVP, Relationship Manager - Heritage Bank of Commerce, a subsidiary of Heritage Commerce, announced that David Casassa has joined the Bank as Senior Vice President, SVP, and Relationship Manager. He will focus on leveraging his extensive network in the North Bay to cultivate loans and deposits in the region. Casassa most recently as SVP and Market Manager at a competing bank in Petaluma, CA.

09:29 EST Carlyle Group announces majority investment in Sciens Building Solutions - Sciens Building Solutions announced that it has reached a definitive agreement to sell a majority stake to funds managed by global investment firm Carlyle. The Company's senior management team, as well as current owner Huron Capital, will retain minority equity stakes in the business. Terms of the private transaction were not disclosed. Greg Nikodem, Managing Director at Carlyle, said, "We're excited to partner with... Sciens' experienced and talented team to fuel the Company's growth in such an attractive market. By combining management's unparalleled knowledge of the fire and life safety industry with our resources and network of relationships, we aim to add value for Sciens' customers, channel partners and employees. This investment is consistent with our demonstrated strategy within the broader business services space, and we look forward to helping the team accelerate their vision of building a best-in-class and differentiated company."

09:28 EST 1stDibs launches 1stDibs Auctions - 1stDibs has launched 1stDibs Auctions, presenting a new way to discover and own the world's most beautiful things. Originally introduced as a listings site in 2001, 1stDibs transitioned to a full e-commerce model in 2016. With the arrival of Auctions, the platform allows guests to place bids on their favorite items-spanning furniture, home decor, art, fine jewelry, watches, handbags and fashion-offering the thrill associated with a treasure hunt and winning a beloved item at an exceptional price. To celebrate this new milestone, 1stDibs teamed up with Jonathan Adler and Simon Doonan to guest curate a collection of their favorite auction finds. The creative dynamos-Adler, a potter, designer and author; and Doonan, a writer, window dresser and fashion commentator-hand-selected an assortment of items that reflect their style sensibilities.

09:27 EST Philips receives grant to improve accessibility of maternal care - Royal Philips announced it has received a USD 15.4 million grant from the Bill & Melinda Gates Foundation to develop an artificial intelligence based application suite to improve the quality and accessibility of obstetric care in low- and middle-income countries, especially in underserved communities. By helping front-line healthcare workers such as midwives to identify potential problems in pregnancy at an early stage, the project aims to significantly reduce the number of women who die as a result of pregnancy - currently around 830 women every day worldwide- while reducing fetal mortality and morbidity. The project plans to develop an application suite that will be deployed on Philips Handheld Ultrasound - Lumify - which is currently in widespread use in community-based mother and child care programs around the world. It also builds on the expertise of the Philips Foundation, providing access to quality healthcare for underserved communities worldwide, including a program in Kenya to educate midwives to deliver ultrasound-based antenatal pregnancy screening in village clinics, while receiving telehealth support from radiologists at distance.

09:26 EST Acacia Research announces licensing pact with Samsung for Wi-Fi 6 patents - Acacia Research (ACTG) announced that its subsidiary, Atlas Global Technologies, has granted a license to Samsung Electronics (SSNLF) related to Atlas Global's Wi-Fi 6 standard essential patents and resolved patent litigation between the two parties. Acacia's Chief Intellectual Property Officer, Marc Booth, commented, "The rapid completion of the first Atlas Global license is a testament to the strength of its portfolio of Wi-Fi 6 standard essential patents." Financial terms are confidential and will not be disclosed.

09:25 EST Tenable Holdings teams with IBM Security X-Force Red - Tenable (TENB) announced an expansion of its strategic relationship with IBM (IBM) Security X-Force Red to deliver comprehensive Active Directory security services that continuously detect and prevent attacks against the Active Directory and connected environment in real-time. By combining the power of Tenable.ad with X-Force Red's team of hackers, organizations can identify and disrupt attack opportunities. Active Directory is a target-rich environment that can, if left vulnerable, offer attackers a route to privilege and control of the entire domain. Leveraging Tenable.ad, the X-Force Red team provides deployment, configuration, support and tool management to identify Active Directory misconfigurations and other weaknesses. From there, the team prioritizes the highest-risk flaws based on weaponization, and manages the complete remediation process from end-to-end. "Vulnerable and misconfigured Active Directories are behind nearly every major cyberattack today. By leveraging known flaws and misconfigurations, bad actors can elevate privileges and move laterally through networks," said Mark Thurmond, chief operating officer, Tenable. "We're excited to partner with X-Force Red to find and fix Active Directory weaknesses before they become tomorrow's attack path."

09:24 EST Exela announces early tender results, extension of early tender time - Exela Technologies announced that it has extended the early tender time from 5:00 p.m., New York City time, on November 9, 2021 until 11:59 p.m., New York City time, on November 24, 2021, with respect to the previously announced exchange offer by certain of its subsidiaries for Old Notes and Old Term Loans as described in the Offering Memorandum. As of the Original Early Tender Time, approximately $318.7 million, or 34.1%, of outstanding Old Notes were tendered for exchange pursuant to the Exchange Offer. Accordingly, Old Notes and Old Term Loans validly tendered and not validly withdrawn at or prior to the Extended Early Tender Time will still be eligible to receive $900 in cash per $1,000 principal amount of the Old Notes and the Old Term Loans, respectively, up to a maximum amount of $225 million in cash. As the cash offer is already oversubscribed, Old Notes and Old Term Loans validly tendered and not validly withdrawn at or prior to the Extended Early Tender Time will be accepted for cash on a pro rata basis. The remainder of Old Notes and Old Term Loans validly tendered and not validly withdrawn at or prior to the Extended Early Tender Time and not accepted for cash will be exchanged into the Issuers' 11.500% First-Priority Senior Secured Notes due 2026 on the basis of $1,000 principal amount of the New Notes for each $1,000 principal amount of outstanding Old Notes and Old Term Loans. The Company expects settlement for the Exchange Offer to occur promptly after the Expiration Time of 11:59 pm, New York City time, on November 24, 2021. The deadline to validly withdraw tenders of the Old Notes and the Old Term Loans was not extended and expired at 5:00 p.m., New York City time, on November 9, 2021.

09:21 EST Lockheed Martin saw $700M in higher supplier costs for August-September period

09:21 EST Lockheed Martin sees end of supply chain issues over the next year - Comments made by acting CFO John Mollard at Baird's 2021 Global Industrial Conference.

09:20 EST Omniq's Dangot Computers awarded $2M order for IHCs - omniQ Corp., majority owner of Dangot Computers Ltd announced that Israel's largest HMO, serving over 4.7 million citizens has chosen Dangot to provide its Intelligent Healthcare Carts to be used in customer's 14 Hospitals, and over 2,000 clinics. The Customer serves over 50% of the Israeli population with clinics and hospitals all over the country is known for its quality, innovation and achieving JCI Accreditation. JCI is a non-for-profit organization that certifies hospitals worldwide based on their high-quality standards and safety, and requires rigorous audits and quality compliance.

09:18 EST Red Rock Resorts to purchase Class A shares, declares $3.00 special dividend - Red Rock Resorts announced that it commenced a "modified Dutch Auction" tender offer to purchase up to $350M in aggregate purchase price of its issued and outstanding shares of Class A Common Stock, par value $0.01 per share, or such lesser aggregate purchase price of Shares as are properly tendered and not properly withdrawn, at a price not greater than $53.00 nor less than $46.00 per Share to the seller in cash, less any applicable withholding taxes and without interest. The tender offer is being made in accordance with the terms and subject to the conditions described in the offer to purchase, the related letter of transmittal and other related materials, as each may be amended or supplemented from time to time. In addition, the company announced that its Board of Directors has declared a special cash dividend of $3.00 per share. The Special Dividend is payable to shareholders of record on November 23, and is expected to be paid on December 22. Shareholders will be entitled to the Special Dividend whether or not they tender their Shares pursuant to the tender offer provided they hold such Shares on the record date. Because shareholders will remain the holder of any Shares they tender until the tender offer expires and the company accepts any such Shares for payment, shareholders will receive the Special Dividend even if they tender their Shares prior to the record date. However, shareholders that acquire any Shares after the record date for the Special Dividend and subsequently tender such Shares pursuant to the tender offer will not receive the Special Dividend with respect to such Shares.

09:16 EST Zynex declares special cash dividend of 10c per share, stock dividend of 10% - Zynex has declared a one-time special cash dividend of 10c per share and a stock dividend of 10% per share. Both dividends are on its Common Stock. The dividends are payable to all common stockholders of record as of the close of business on January 6, 2022, payable on or about January 21, 2022. Based on the current number of shares outstanding the cash dividend is expected to result in an aggregate distribution of approximately $3.5M. The stock dividend will result in an issuance of approximately 3.5 million additional shares of common stock.

09:15 EST Foothills Exploration announces results for Phase 1 soil geochemical survey - Foothills Exploration announces that it has received "encouraging" results for Phase 1 of its previously announced soil geochemical survey on a portion of the Company's acreage in the Beaver Creek East, BCE, project in Fremont County, Wyoming. The BCE soil hydrocarbon geochemical survey carried out over approximately 20 square miles of the Company Exploration Development Area in Fremont County, Wyoming has successfully documented oil and gas microseeps that will help focus the Company's Master Drilling Plan Development. "The initial results of our geochemical program at Beaver Creek East are quite promising and support our geological and technical analysis," said Kevin Sylla, the Company's Executive Chairman. "We look forward to the next phase of the geochemical program coupled with our 2-D seismic interpretation currently underway as we further evaluate the best locations for our drilling program," continued Sylla.

09:14 EST iFresh enters a Master Product Supply Agreement with Alibaba.com, Tmall Global - iFresh (IFMK) announced it has entered into a Master Product Supply Agreement with Alibaba.com (BABA) Singapore E-Commerce Private. This Agreement establishes a cross-border trade partnership, enabling iFresh to sell American food and products to China via Tmall Global's cross-border e-commerce platform. Now it is formally launched on the cross-border e-commerce platform. Under the terms of the Agreement, iFresh will bring American food and products to Tmall Global, including products like infant formula, dried fruit, coffee, and other snacks. The products will be sent to Tmall Global's overseas warehouse in the US. Based on each sales order, Tmall Global will provide one-stop control and the management service of sorting, packaging, and distribution. Long Deng, Chairman of iFresh, commented, "Selling cross-border is the perfect opportunity for American food and products to enter the Chinese market quickly. We will work with China's leading cross-border e-commerce B2C platform from Alibaba Group through this Agreement, allowing us to make our vision of scaling iFresh to the global market a reality. This Agreement with Tmall Global marks our collaboration with its overseas warehouse to drive massive growth of our wholesale product sales. We are confident that the partnership will help accelerate iFresh into new global markets while benefiting the Company's financial performance, creating exceptional value for our shareholders."

09:12 EST Helius Medical announces pricing of $9.6M underwritten public offering - Helius Medical Technologies announced the pricing of an underwritten registered public offering of 1,204,375 shares of its common stock at a price to the public of $8.00 per share. All of the shares of common stock to be sold in the offering will be sold by the Company. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 180,656 shares of its common stock at the public offering price less the underwriting discount. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters' option to purchase additional shares, are expected to be approximately $9.6 million. The offering is scheduled to close on or about November 12, 2021, subject to customary closing conditions. The Company intends to use the net proceeds from this proposed offering for funding operations, working capital and other general corporate purposes.

09:11 EST Telos announces channel agreement with DLT Solutions - Telos (TLS) announced that the Telos solutions portfolio has been added to "some of the nation's largest public sector contract vehicles" through the company's channel agreement with DLT Solutions, a wholly-owned subsidiary of Tech Data Corporation and part of the TD SYNNEX (SNX) family, who is the premier government solutions aggregator that specializes in understanding the information technology needs of the U.S. federal, state, local and education markets. DLT will offer Telos solutions across its channel ecosystem and through the company's OMNIA Partners Public Sector Software IDIQ, National Cooperative Purchasing Alliance - Systems and Information Management Software and The Interlocal Purchasing System contracts. DLT will add Telos' cybersecurity portfolio to select federal contract vehicles the company holds in the coming months.

09:09 EST Under Armour selects AWS as preferred cloud provider for SAP environments - Amazon Web Services (AMZN) announced that Under Armour, Inc. (UA,UAA) has selected AWS as its preferred cloud provider for SAP to increase resilience, enhance security, and provide more significant insights across its business. The athletic performance brand completed the migration of its SAP environments to AWS earlier this year, providing the foundation for improving performance and visibility across its design, merchandising, planning, manufacturing, supply chain, and sales distribution channels. Under Armour will now integrate its SAP environments with AWS's broad and deep set of technologies, including analytics, machine learning, compute, and storage. Powered by the world's leading cloud, this modernization brings a range of AWS capabilities to fuel innovation in areas like 3D apparel and footwear design, digitally connected footwear and apparel, resource-efficient production, direct-to-consumer sales, and global wholesale distribution.

09:07 EST Twilio names Eyal Manor chief product officer, Dana Wagner chief legal officer - Twilio (TWLO) announced two additions to its leadership team. Eyal Manor is joining as chief product officer, effective November 15 and Dana Wagner is joining as chief legal officer, effective December 13. Manor will oversee the execution of Twilio's future product roadmap, working to deliver on its vision to build the leading customer engagement platform. Wagner will lead the company's legal, government affairs, regulatory compliance, and privacy teams as Twilio continues to expand and scale globally. Both Manor and Wagner will join Twilio's executive management team, and Wagner will become its corporate secretary. Manor will report to Twilio's co-founder and CEO Jeff Lawson and Wagner will report to Twilio's COO Khozema Shipchandler. Eyal Manor joins Twilio from Google (GOOG) where he was VP and GM of engineering and product. Wagner will be joining Twilio from Impossible Foods, where he was chief legal officer and corporate secretary and oversaw the company's legal, policy, quality control and security operations.

09:06 EST Accenture Federal Services wins $618M U.S. Marshals service task order - Accenture Federal Services, AFS, a subsidiary of Accenture has been awarded a $618M cost plus award fee task order to enhance and modernize the United States Marshals Service's, USMS, mission-critical IT systems. The USMS supports the federal justice system with protecting the federal judiciary, apprehending federal fugitives, transporting federal prisoners, and other law enforcement duties. Under the seven-year task order, awarded through the Alliant 2 Governmentwide Acquisition Contract, GWAC, AFS builds upon a previous five-year USMS task order for program management and IT application development services. This scope of work includes a continuation of case management modernization along with expanded advanced analytics, mobile application development, cloud, biometrics, and geospatial capabilities. The comprehensive, integrated technology effort supports the agency in continuing to roll out emerging technologies, such as automation, with the goal of retiring outdated legacy systems, enhancing security, and reducing costs.

09:02 EST ViacomCBS announces new global deal with Twitter - ViacomCBS (VIACA, VIAC) and Twitter (TWTR) announced a new, multi-year global agreement to deliver premium digital content around ViacomCBS' biggest live events, hit shows and iconic franchises from the company's leading portfolio of entertainment, news and sports brands, including BET, CBS Television Network, CBS News, CBS Sports, Channel 5, CMT, Comedy Central, MTV, Network 10, Nickelodeon, Paramount Network and Telefe. Paramount+ will also host three Twitter Watch Parties, in partnership with Twitter, to bring fans together, fuel conversation and build community around select highly anticipated original series. Each of the tentpole programs will be eligible for Twitter marketing support and brand sponsorship sales rights via Twitter's Amplify program, which marries ViacomCBS' premium video with Twitter's paid reach and targeting. ViacomCBS will also tap into a broad range of Twitter marketing features from live video and real-time highlights to Twitter Moments. The partnership covers all global markets in which Twitter and ViacomCBS operate. Financial terms of the agreement were not disclosed.

09:00 EST Enlivex authorized to expand Phase IIb Allocetra trial by Spanish AEMPS - Enlivex Therapeutics announced that the Spanish Agency of Medicines and Medical Devices, AEMPS, has authorized the expansion of the Company's Phase IIb trial evaluating Allocetra in severe and critical COVID-19 patients with acute respiratory distress syndrome, ARDS, to sites in Spain. The placebo-controlled trial, which is currently enrolling patients at clinical trial sites in Israel, is expected to recruit up to 152 severe or critical COVID-19 patients. It is designed to assess the safety and efficacy of Allocetra when administered in addition to standard of care treatment. The trial's two primary endpoints are ventilation-free survival and recovery for each of the two sub-populations of patients in the study. Oren Hershkovitz, Ph.D., CEO of Enlivex, commented, "We are very pleased to have regulatory clearance to expand our COVID-19 trial to Spain. We believe AEMPS' decision to authorize this expansion, together with their prior decision authorizing the expansion of our sepsis trial, speaks to Allocetra's broadly applicable mechanism of action, the strength of our clinical datasets, and the rigor of our study designs and manufacturing process. The inclusion of several European countries in our ongoing clinical trials is an important component of our regulatory strategy, and one that we plan to continue executing by working with regulatory agencies in additional countries."

08:58 EST Cornerstone Building Brands to acquire Union Corrugating Holdings - Union Corrugating Company Holdings announced that it has entered into a definitive agreement to be acquired by Cornerstone Building Brands. Cornerstone Building Brands is the largest manufacturer of exterior building products for residential and low-rise non-residential buildings in North America. The acquisition is subject to regulatory approval and customary closing conditions and is expected to be finalized later this year.

08:56 EST Meridian Bioscience receives FDA EUA for Revogene SARS-CoV-2 assay - Meridian Bioscience announced that their Revogene SARS-CoV-2 assay was granted Emergency Use Authorization by the U.S. FDA. Meridian expects to begin shipping this product before the end of its fiscal first quarter, ending December 31.

08:54 EST Huadi International announces cooperation agreement with Zhejiang Lanneng - Huadi International announces that the Company entered into a strategic cooperation framework agreement on October 28, 2021 with Zhejiang Lanneng Gas Equipment to jointly develop and produce high-pressure hydrogen storage tank stainless steel pipe. Pursuant to the Agreement, both parties will start off using their respective resources advantages to formulate a manufacturing plan of the high-pressure hydrogen storage tank stainless steel pipe. Then, HUDI will be responsible for producing the stainless steel liner pipes and delivering qualified liner pipes to Lanneng according to the manufacturing plan. Lanneng will complete the production of the high-pressure hydrogen storage tank with liner pipes wrapped by carbon fiber. Di Wang, Chairman of the Company, commented: "We are excited to work with Lanneng under the framework of this cooperation agreement. Our cooperation targets on the development and production of hydrogen energy storage tank, which could be used for the new energy vehicles. In recent years, we have seen a substantial market switch from traditional fuel vehicles to new energy vehicles such as electronic vehicles. I believe the new energy vehicles will become the next super-hot sector, as it has more endurance and replenishment capacities comparing to the fuel vehicles. We are initiatively focusing on the technology of tankage in China and will show our business prospect in the vehicle industry in the future. We believe new energy vehicle is the trend for the coming future.

08:52 EST Portage Biotech hosting KOL webinar on iNKT cells - Portage Biotech announced that it will host a key opinion leader, KOL, webinar on the role iNKT cells play in anticancer immune response and how iNKT targeting can be leveraged to expand the immuno-oncology landscape, Thursday, November 18, 2021, at 10a.m. Eastern Time.The webinar will feature presentations by Mitchell Kronenberg, Ph.D., from the La Jolla Institute for Immunology, and Anastasios Karadimitris MBBS, Ph.D. MRCP FRCPath, from Imperial College London. Dr. Kronenberg will provide an overview on invariant natural killer T cell, iNKT, cells and their mechanism of action to enable multiple parts of the immune system to attack and kill cancer. Dr. Karadimitris will discuss the current iNKT clinical data landscape. Portage Biotech's Chief Executive Officer and Director Ian Walters, M.D., MBA, will then discuss the company's novel clinical development strategy and timing of data from its ongoing clinical trials.

08:49 EST Bigg Digital Assets announces it has fully integrated Syscoin into its ecosystem - BIGG Digital Assets, owner of Blockchain Intelligence, announces it is the first blockchain analytics service to fully integrate Syscoin - a third generation blockchain - into its ecosystem. Syscoin is developed by Blockchain Foundry. Syscoin, a proof-of-work blockchain with a hashrate second only to Bitcoin, is a computing platform combining both Ethereum and Bitcoin protocol into one system.

08:45 EST Omnicell and Fresenius Kabi team to enhance controlled substances management - Omnicell, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Omnicell's Controlled Substance Dispenser, CSD, is a leading high-volume, automated single dose dispensing solution designed to help pharmacies better manage controlled substances, reduce diversion, and save nursing time. By providing only one dose at a time, the CSD is designed to eliminate the need for countbacks and decrease the time required to resolve discrepancies to provide nurses more time for direct patient care and discourage diversion.

08:44 EST Hepion announces poster of results on CRV431 to be at Liver Meeting - Hepion Pharmaceuticals announced that results from a study conducted by Dr. Philippe Gallay's research group at The Scripps Research Institute examining the anti-tumor mechanism of the Company's lead drug candidate, CRV431, will be available as an e-poster at the Liver Meeting 2021, hosted by the American Association for the Study of Liver Diseases, to be held virtually November 12-15, 2021. Poster Details: Title: "Cyclophilin D Knockout Significantly Prevents HCC Development in a Streptozotocin-Induced Mouse Model of Diabetes-Linked NASH."

08:42 EST BK Technologies gets order for 500 KNG2 Series radios from Cal Fire - BK Technologies announced that the California Department of Forestry and Fire Protection has placed an order for 500 of BK's KNG2 Series radios for purchase and deployment. BK's President, Tim Vitou, commented, "We are pleased to have this opportunity to continue to support CAL FIRE's portable communications needs with our KNG2 Series radios. The agency's fire professionals play a critical role keeping Californians safe from the dangerous wildfires we've all seen on the news, and with their vast geographic area of responsibility, including non-fire rescue and emergency services, it is integral that CAL FIRE's communications technology is robust and reliable to ensure effective and secure field operations. We're delighted to provide our KNG2 Series portable communications technology to help CAL FIRE in its mission to keep local communities safe and protected during fire emergencies as well as other situations requiring emergency response efforts."

08:42 EST Pipestone Energy sees 2022 production 34,000-36,000 boe/d - In 2022, Pipestone plans to spend $180 - $200 million, which includes 21 wells drilled, and 24 wells completed, equipped, and brought on production. This capital program is forecast to drive full year average 2022 production of 34,000 - 36,000 boe/d. At the guidance range midpoint, Pipestone forecasts generating cash flow of $340 million and free cash flow of $150 million at US$70 WTI $3.50 AECO

08:41 EST Pipestone Energy sees 2021 production 24,000-26,000 boe/d

08:39 EST CN Energy establishes new subsidiary to expand into water purification market - CN Energy plans to expand into the dollar water purification market. The global water purification market is projected to grow from $29.12B in 2021 to $47.53B in 2028 at a CAGR of 7.2% in the forecast period, 2021 to 2028. It has established a new subsidiary to focus on this new market opportunity in order to participate in this expanding market. The new subsidiary, Zhejiang CN Energy, is located in the Economic and Technological Development Zone of Lishui City, Zhejiang Province. Construction is underway on facilities for manufacturing, R&D, sales and marketing, and corporate operations, with a targeted annual output capacity of 36,000 tons of high-precision fine wading activated carbon.

08:38 EST Charles River proposes partnership with SC Department of Natural Resources - Charles River Laboratories International, Inc. is reinforcing its position as an environmental steward and its commitment to the Company's South Carolina operations and the critical role the Charleston-based team plays in the biomedical industry. Most recently, Charles River has proposed a partnership with the state of South Carolina Department of Natural Resources that will reinforce the stringent regulatory oversight already in place, sustain Charles River's work-which is critical to patient safety-and fund research to continue to ensure that horseshoe crab populations are protected and thriving.

08:39 EST Hyzon Motors, TC Energy partner on modular hydrogen production hub development - Hyzon Motors (HYZN) and TC Energy (TRP), announced an agreement to collaborate on development, construction, operation, and ownership of hydrogen production facilities across North America. The hydrogen production facilities will be used to meet hydrogen fuel cell electric vehicle demand by focusing on low-to-negative carbon intensity hydrogen from renewable natural gas, biogas and other sustainable sources. The facilities will be located close to demand, supporting Hyzon back-to-base vehicle deployments. Under the agreement, the companies will evaluate sites across multiple states and provinces to develop hydrogen production facilities with the goal of hydrogen delivery to fuel heavy duty vehicles. The hubs will be prioritized near existing and potential customer demand with a goal to produce up to 20 tonnes of hydrogen per hub per day. TC Energy will operate the hubs, supply the power and gas commodities, and provide asset development, management services, and power and gas sales marketing.

08:36 EST MICT, Inc. files preliminary proxy to expand authorized share count - MICT announces the filing of a preliminary proxy statement, which includes the proposed increased expansion of authorized shares to 425 million shares from 250 million shares. The Company remains actively searching for accretive external acquisitions and believes the additional authorized shares will help facilitate such potential transactions in the Company's short, medium, and long-term horizon. The Company's expansion strategy is an important component of the Company's future growth plans and believes such additional shares will be a highly useful tool in connection therewith. With the Company's significant cash reserves, the additional authorized shares opens up a significant number of opportunities for the Company.

08:36 EST T. Rowe Price reports preliminary AUM $1.67T at October 31 - Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $3.1B in October 2021 and $21.5B for the year-to-date period ended October 31, 2021. These client transfers include $2.2B and $14.9B, respectively, transferred to the target-date retirement trusts during October and the year-to-date period.

08:34 EST Omnicell and Fresenius Kabiteam to enhance controlled substances management - Omnicell, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Omnicell's Controlled Substance Dispenser, CSD, is a leading high-volume, automated single dose dispensing solution designed to help pharmacies better manage controlled substances, reduce diversion, and save nursing time. By providing only one dose at a time, the CSD is designed to eliminate the need for countbacks and decrease the time required to resolve discrepancies to provide nurses more time for direct patient care and discourage diversion

08:34 EST ADP raises quarterly dividend by 12% to $1.04 per share - ADP approved an 11c increase in the quarterly cash dividend to an annual rate of $4.16 per share. The new quarterly dividend rate of $1.04 per share will be distributed on January 1, 2022 to shareholders of record on December 10, 2021.

08:34 EST Qorvo announecs two studies on Qorvo Omnia SARS-CoV-2 Antigen Test - Qorvo announced that two recent studies confirm that the Qorvo Omnia SARS-CoV-2 Antigen Test efficiently detected SARS-CoV-2 variants circulating in the United States. Of the two studies, one was conducted by Emory University, Georgia Institute of Technology, and Children's Healthcare of Atlanta for the National Institutes of Health, NIH, Rapid Acceleration of Diagnostics, RADxSM, initiative and the other was performed by the Qorvo Biotechnologies Research and Development laboratory in Plymouth, Minnesota. As a RADxSM-supported company, Qorvo regularly validates the Omnia SARS-CoV-2 Antigen Test for new variant response in partnership with the RADxSM variant taskforce. Qorvo also performs internal testing on recombinant antigens with mutations specific to circulating variants. Recent work has focused on the Delta variant given significant national and international interest. James Klein, President of Qorvo Biotechnologies, said, "These two studies of the SARS-CoV-2 variants demonstrate the robustness of the Qorvo Omnia SARS-CoV-2 Antigen Test in detecting circulating variants in the U.S. population. Accurate test results are critical to healthcare personnel as we continue the fight against this virus. Qorvo is pleased to play an active role in curbing the spread of SARS-CoV-2 in the U.S."

08:32 EST Hershey to acquire Dot's Pretzels, Pretzels Inc. for $1.2B - The Hershey Company announced it has entered into a definitive agreement to acquire Dot's Pretzels LLC, the owner of Dot's Homestyle Pretzels, the fastest-growing scale brand in the pretzel category. Hershey also announced today it has entered into a definitive agreement to acquire Pretzels Inc. from an affiliate of Peak Rock Capital, a private investment firm with numerous investments in the food and beverage industry. Pretzels Inc. is a co-manufacturer of pretzels for Dot's Pretzels and several other customers and is a leading innovator in the pretzel category. Based in Bluffton, Indiana, Pretzels Inc. operates three manufacturing locations in Indiana and Kansas. When the transactions are completed, these three manufacturing locations would be in addition to four pretzel-seasoning facilities to be acquired with Dot's. The acquisition of Pretzels Inc. would give Hershey deep pretzel category and product expertise and the manufacturing capabilities to support Dot's growth and future pretzel innovation as well as the continued growth in the entire pretzel category through Pretzels Inc.'s leading co-manufacturing capabilities. The total purchase price for these two proposed acquisitions is approximately $1.2 billion, or approximately $1 billion of investment net of expected future tax benefits. It will be financed with cash on hand as well as short-term borrowings. The estimated aggregate net sales for the two businesses were approximately $275 million for the 12 months ended September 2021. The combination of these two strategic acquisitions is expected to be slightly accretive to reported earnings per share in 2023 and adjusted earnings per share in 2022. The acquisitions are subject to customary regulatory approvals and are expected to close by the end of 2021.

08:29 EST Ligand announces plans for OmniAb to become standalone public company - Last night, Ligand Pharmaceuticals announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand's existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business. "The spin-off is intended to create two companies with dedicated operational focus, business-specific capital allocation, agility to meet partner needs, and compelling focused investment profiles," Ligand stated. "Based on initial management and advisor review, an IPO and eventual distribution of OmniAb shares to Ligand shareholders is the leading option under consideration at this time. The IPO would be of newly issued shares of OmniAb, Inc., which would include the Ab Initio computational antigen design technology, Icagen's ion channel technology, the xPloration high-throughput screening technology, and the suite of OmniAb transgenic animals used for antibody discovery. In an IPO, Ligand expects OmniAb to issue less than 20% of its common stock, with Ligand retaining the remaining interest, which would eventually be distributed to Ligand stockholders in a manner generally intended to qualify as a tax-free transaction. Ligand's OmniAb strategic review is in response to the ongoing success of OmniAb, as well as the opportunity to unlock the value of this business. Ligand's Board of Directors has not approved a specific course of action, and Ligand will continue to evaluate other options to optimize value and ensure flexibility to invest in growth. There can be no assurance that this process will result in Ligand pursuing a particular transaction or consummating any such transaction," the company said.

08:26 EST Finch Therapeutics announces transition of Chief Medical Officer - Finch Therapeutics announced that Zain Kassam, MD, MPH has elected to step down as Chief Medical Officer in order to return to Canada to attend to a family health matter. Dr. Kassam will continue to support the company as a special advisor. Debra Silberg, MD, PhD will serve as interim CMO to support the company through this transition and search for a new CMO.

08:23 EST Anthem to acquire Integra Managed Care, terms undisclosed - Anthem announced that the company has entered into an agreement to acquire Integra Managed Care, "a Managed Long-Term Care Plan in New York that helps adults with long term care needs and disabilities live safely and independently in their own home," said the company in a statement. "This acquisition aligns with our goal of growing Anthem's Medicaid business, while serving our members with a comprehensive and coordinated approach to care," said Felicia Norwood, Executive Vice President of Anthem's Government Business Division. "Like Anthem, Integra has established connections with community groups to gain a deeper understanding of how to best support the whole-health needs of the people we are privileged to serve." Anthem is acquiring Integra from a wholly-owned indirect subsidiary of Personal Touch Holding Corporation. Financial terms of the transaction were not disclosed. Anthem's legal advisors are White & Case, Hinman Straub, and Lewis Rice. Ruskin Moscou Faltischek, Greenberg Taurig, and ESOP Law Group are acting as legal advisors for Integra. Stifel acted as the exclusive financial advisor to Integra in this transaction.

08:23 EST Talkspace awarded $3M grant from NIMH to study CPT - Talkspace announced it has been awarded a $3M grant from the National Institute of Mental Health, or NIMH, to study the effectiveness of Cognitive Processing Therapy, or CPT, - a treatment for post-traumatic stress disorder, or PTSD, - in a virtual setting. The new study will build on preliminary research undertaken by Talkspace which found that combining CPT with virtual tools could reduce trauma symptoms by twice as much over treatment as usual, and in less time. The pilot study of 60 participants utilized a hybrid model that offered educational experiences in conjunction with therapy. Results demonstrated that patients are able to achieve greater outcomes and that specially trained trauma therapists are able to assist more individuals in processing events and challenges than they could before.

08:21 EST Gold Standard Ventures announces advancement of key milestones - Gold Standard Ventures announced updates on its permitting progress, Feasibility Study, and construction capital financing process. The Company is currently in the Environmental Impact Statement process pursuant to the National Environmental Policy Act. SWCA Environmental Consultants has been engaged to manage the EIS process on behalf of the Bureau of Land Management. Preparation of the Notice of Intent has commenced and is anticipated to be submitted to the BLM in Washington, DC, in Q4 2021. Once the Notice of Intent is published in the Federal Register, public scoping meetings can commence. Based on the EIS timeline developed amongst the Company, SWCA, and the BLM, the timing of the Record of Decision permit is anticipated to be in Q1 2023. In conjunction with the permitting process, work is advancing to secure site access and water rights. Feasibility Study development, led by M3 Engineering, continues to advance. As previously reported, the Company has been working on the conversion of certain Inferred Mineral Resources to Mineral Reserves to support a longer mine life. In-fill drilling results at Pinion indicate the possibility of converting approximately 350,000 contained ounces of gold for inclusion the FS mine plan. The results of mine plan optimization work indicates that 200-ton capacity haul trucks will likely provide more economic benefit than the 150-ton capacity haul trucks that were contemplated in the 2020 Pre-Feasibility Study. The larger sized haul trucks provide the potential benefit of lower mining unit costs through increased efficiency and reduced labour costs. Metallurgical and processing studies are ongoing and focused on leach kinetics, leach pad design, and metallurgical recovery models. Although it is anticipated that the FS will include the construction of a high-pressure grinding rollers crushing facility in future years, metallurgical studies indicate the possibility of processing all Dark Star and Pinion ore as a run-of-mine heap leach operation. This scenario has the potential of unlocking significant savings on expansion capital expenditures, sustaining capital expenditures, and processing unit costs than what was contemplated in the PFS, with an offsetting impact of slightly lower estimated gold recoveries. The Company will continue to explore this option with its consultants. Although toll processing of approximately 32,000 ounces of gold in transitional and sulphide material at Dark Star was contemplated in the PFS, this is not expected to be included in the upcoming FS. The Company believes there remains an attractive opportunity to extract value from this material, in addition to the potential for new mineralization directly under the Dark Star North PFS pit boundary as described in the Company's news release dated September 13, 2021. However, the economic analysis necessary to support the processing of this material will not be completed to a feasibility level for the upcoming study. Certain changes to initial capital expenditure estimates of direct costs, indirect costs, and contingencies are anticipated in the upcoming FS, as expected in relation to the planned increased scope and scale of the project compared to the PFS. Gold Standard is committed to responsible mining and is focused on building and operating in the most environmentally sensitive way possible. Based on the timing of ongoing metallurgical column tests of drill core that represents Pinion Phases 4 and 5, it is anticipated that the Feasibility Study will be released in Q1 2022. Preparatory work continues to advance on Gold Standard's construction capital financing process, along with our advisor Cutfield Freeman & Co. Lending capacity for the South Railroad Project is anticipated to be robust, due to strong forecasted free cash flows over the first five years during the mining of the Dark Star deposit as outlined in the PFS. As announced in the Company's news release dated July 16, 2020, Orion Mine Finance has committed to providing Gold Standard with a term sheet to provide up to US$200 million of construction financing support. In addition, the Company has received interest from the following capital providers about participating in the SRP construction capital financing process: mining focused alternative lenders, commercial banks, streaming and royalty companies, and multinational precious metal producers. Gold Standard anticipates commencing the construction capital financing process in conjunction with the release of the SRP Feasibility Study in Q1 2022. The Company will prioritize a construction financing package that provides the most attractive long-term benefits to Gold Standard shareholders.

08:18 EST MEI Pharma, Kyowa Kirin announce FDA grants ODD to zandelisib for FL - MEI Pharma and Kyowa Kirin an affiliate of Kyowa Kirin announced that the U.S. Food and Drug Administration, FDA, granted orphan-drug designation, ODD, to zandelisib for the treatment of follicular lymphoma. Orphan-drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a disease or condition that affects fewer than 200,000 individuals in the U.S. ODD granted therapies entitle companies to development incentives including tax credits for qualified clinical trials, exemptions from certain FDA application fees, and the potential of seven years of marketing exclusivity in the event of regulatory approval. ODD does not shorten the duration of the regulatory review or approval process. Zandelisib, a selective PI3Kdelta inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with B-cell malignancies. In March 2020 the U.S. FDA granted zandelisib Fast Track designation for treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies. In April 2020, MEI and Kyowa Kirin entered a global license, development, and commercialization agreement to further develop and commercialize zandelisib. MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales. Kyowa Kirin has exclusive commercialization rights outside of the U.S. and will pay MEI escalating tiered royalties on ex-U.S. sales.

08:17 EST Pluristem receives approval grant from IIA to develop CRISPR PLX platform - Pluristem Therapeutics announced that it has received approval for an additional grant from the Israel Innovation Authority, IIA, to support research based on its cutting-edge PLX platform. The grant comes as part of the Company's work as part of the CRISPR-IL consortium, which the IIA funds through its Bio-Convergence Program. The IIA approved a new budget for the Consortium to continue its work for an additional 18 months after evaluating its activity and results over the past 18 months. As part of the budget, Pluristem is expected to receive approximately $583,000 to continue its work in developing a new generation of PLX cells based on the use of CRISPR technology to genetically program desired cell functions in future allogenic products. Yaky Yanay, CEO and President said: "The evaluation of the CRISPR-IL Consortium's work over the last 18 months was successfully completed. The IIA's continued investment in Pluristem's participation in this work provides further opportunity to push forward the development of next generation allogeneic cell therapies. We continue to believe that the integration of CRISPR technology in our PLX platform holds great potential to develop the treatments of the future, and the IIA's approval of additional funds is validation of that belief."

08:14 EST Autoliv increases quarterly dividend 3% to 64c from 62c per share - Autoliv announced that its quarterly dividend will be increased by 3% to 64c per share, from 62c, for the fourth quarter of 2021. The dividend will be payable on Monday, December 13 to Autoliv shareholders of record on the close of business on Monday, November 29. The ex-date will be Thursday, November 25, for holders of common stock listed on the New York Stock Exchange as well as for holders of Swedish Depository Receipts listed on Nasdaq Stockholm.

08:13 EST MeiraGTx announces upcoming milestones - Provide a clinical update of the Phase 1 AQUAx trial of AAV-AQP1 for the treatment of Grade 2/3 radiation-induced xerostomia in early December 2021. Complete enrollment of the Phase 1 AQUAx trial of AAV-AQP1 for the treatment for Grade 2/3 radiation-induced xerostomia during the fourth quarter of 2021. The Company will hold a Research and Development Day in December 2021 where additional data on its synthetic riboswitch gene regulation platform as well as the Company's proprietary promoter platforms will be presented. File an Investigational New Drug application for AAV-GAD for the treatment of Parkinson's Disease during the fourth quarter of 2021. Initiate, with Janssen, later stage clinical studies for AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia in 2022. Initiate a Phase 3 pivotal trial of AAV-RPE65 for patients with RPE65-associated retinal dystrophy in early 2022.

08:11 EST GCM Grosvenor board approves 11% dividend increase to 10c per share - GCM Grosvenor's Board of Directors approved a $0.10 per share dividend payable on December 15, 2021 to shareholders on record December 1, 2021

08:08 EST Velocity Acquisition, BBQGuys agree to terminate business combination - BBQ Holding (BBQG) and Velocity Acquisition Corp (VELO) announced that the companies have mutually agreed to terminate their previously announced agreement and plan of merger, effective immediately. The parties decided to terminate the Business Combination Agreement as a result of current supply chain factors that are affecting the results of the BBQGuys business and timing of closing the transaction. Doug Jacob, Founder of Velocity, stated, "BBQGuys is a fantastic company with a proven track record of growth and we wish them continued success as they emerge from the current supply chain conditions that are challenging so many companies. We know they will continue to be a strong player in the backyard space. We will continue our efforts to capitalize on digital transformation trends and are confident in our ability to combine with a blue-chip company that will maximize value for our shareholders."

08:07 EST Rain Therapeutics announces anticipated milestones - Anticipated Near-term Milestones Milademetan MDM2-Amplified Phase 2 Basket Trial Phase 2 trial anticipated to commence enrollment this quarter Interim data anticipated in the second half of 2022; Milademetan MCC Phase 2 Trial Phase 2 trial anticipated to commence in mid-2022; Milademetan Dedifferentiated Liposarcoma Phase 3 Trial Data anticipated in 2023 RAD52 Research Program Lead candidate selection anticipated in 2022

08:06 EST Merck to supply 1.6M courses of molnupiravir to Japan for $1.2B upon approval - Merck and Ridgeback Biotherapeutics announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6M courses of molnupiravir, an investigational oral antiviral medicine. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck's applications for the potential authorized use of molnupiravir are under review by Japan's Pharmaceuticals and Medical Devices Agency, the FDA, and the European Medicines Agency. Molnupiravir is authorized in the United Kingdom for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. Under the agreement, if molnupiravir receives authorization or approval by Japan's Pharmaceuticals and Medical Devices Agency, Merck will supply approximately 1.6M courses of molnupiravir to the Japanese government for approximately $1.2B including applicable taxes. In anticipation of results from the Phase 3 MOVe-OUT clinical trial, and the potential for regulatory authorization or approval, Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to produce 10M courses of treatment by the end of 2021, with at least 20M courses to be produced in 2022. In addition to the Japan agreement, as part of its global efforts to accelerate access, Merck has also entered into supply and purchase agreements with the governments of several other countries and is currently in discussions with additional governments.

08:04 EST Rain Therapeutics expects cash to provide runway through completion of trials - As of September 30, 2021, Rain had $150.1 million in cash, cash equivalents and short-term investments. Rain expects that its quarter-end cash position will provide runway to continue advancing its R&D pipeline and complete all three planned clinical trials of milademetan.

08:03 EST Unity Biotechnology announces upcoming milestones - UBX1325 Phase 2a proof of concept study in DME had a first patient dosed in June 2021 and is actively recruiting patients, with information about that trial available here. Twelve-week safety and efficacy data are expected in the first half of 2022. UBX1325 Phase 2 proof of concept study in AMD is expected to initiate in the first half of 2022, with twelve-week safety and efficacy data expected in the second half of 2022. UBX2050 and UBX2089 expected to enter IND-enabling studies in 2022.

08:02 EST 9 Meters Biopharma announces immuno-oncology collaboration with Gustave Roussy - 9 Meters Biopharma announced a collaboration agreement with Gustave Roussy, "a leading cancer center in Villejuif, France, using 9 Meters' small molecule tight junction microbiome modulator NM-102," said the company. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into systemic circulation. This collaboration adds to an initial 14-month preclinical research project initiated in March 2019, which focused on the relationship between intestinal microbiome composition and systemic responses to cancer treatments such as chemotherapy and immune checkpoint inhibitors . Specifically, the work tested the hypothesis that the therapeutic effect of ICIs, such as antibodies to CTLA-4 and PD-1, might be affected by preventing bacterial antigens, toxins and certain metabolites in the gut from interacting with the host immune system via NM-102's posited role in preventing gut microbial matter from entering systemic circulation. These studies showed that NM-102 was effective both when alone and when combined with ICIs in a transgenic mouse model of spontaneous aggressive skin melanoma. Furthermore, the combination of NM-102 with ICIs improved survival compared to ICIs alone. Under the terms of the collaboration agreement, Gustave Roussy will investigate how tumors in preclinical models may effect intestinal integrity and in turn compromise the fitness of the host's immune system and its capacity to respond to ICIs. Further work is planned to decipher the mechanism of NM-102 and its effects on intervening on the epithelial layer of the GI tract, as well as its potential translation to ICI efficacy in preclinical cancer in vivo models. The Company intends to move forward with an IND-enabling pathway.

08:00 EST Gritstone announces preclinical data on second-generation COVID-19 vaccine - Gritstone bio published "positive" preclinical data in non-human primate models from the CORAL next-generation COVID-19 vaccine program against SARS-CoV-2, the coronavirus that causes COVID-19 disease. In a non-human primate challenge study, immunization with a self-amplifying mRNA, SAM, vaccine protected rhesus macaques against SARS-CoV-2 infection as either a homologous prime-boost regimen or as a single boost following an optimized chimpanzee adenoviral, ChAd, vector prime. "Advancing new vaccine strategies, like our SAM platform, may help avoid further propagation and mutation of SARS-CoV-2 and potentially address delays in global vaccination. These data, combined with clinical data we are currently generating, continue to validate the concept of broad and potent T cell and neutralizing antibody responses following SAM as a 2-dose regimen, or as a boost following an initial ChAd dose," said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone. "During situations like a pandemic, a potent SAM homologous vaccine platform can offer simplicity in manufacturing and rollout, and our AI antigen prediction platform, EDGE, is likely to enable accelerated design of vaccines that contain both antibody and key T cell antigens from novel pathogens. A heterologous ChAd prime and SAM boost regimen, the so-called "mix-and-match" approach, may provide a potent option to those with a weakened immune system, particularly cancer patients receiving B cell-directed therapies that weaken antibody responses to mRNA vaccines. We look forward to sharing preliminary data from our first CORAL trial early in the first quarter of 2022." In the study, a SAM vaccine encoding a prefusion stabilized SARS-CoV-2 spike glycoprotein demonstrated potent cellular and humoral immune responses at low doses in mice and rhesus macaques. The homologous prime-boost vaccination regimen of SAM at 3, 10 and 30 microgram induced potent neutralizing antibody titers in rhesus macaques at all dose levels. Spike-specific T cell responses were observed in all dose groups. SAM vaccination provided protective efficacy against SARS-CoV-2 challenge as both a homologous prime-boost and as a boost following ChAd prime, demonstrating reduction of viral replication in both the upper and lower airways. Protection was most effective with a SAM prime-boost vaccination regimen at 10 and 30 microgram and with a ChAd/SAM heterologous prime-boost regimen.

07:59 EST Ceridian acquires DataFuZion HCM, terms not disclosed - Ceridian announced it has acquired substantially all of the assets of DataFuZion HCM, Inc., an HCM technology company. In today's increasingly borderless world of work, organizations are continually challenged to address complex compliance rules and regulations. Forward-thinking leaders need to harness the power of technology to help maintain compliance, create efficiencies, and improve automation and accuracy. The acquired technology includes specific features for certified payroll reporting, prevailing wage rate calculations, incentive payments, union rate calculations, and complex general ledger reporting. This acquisition extends Ceridian's leadership in industries often experiencing complex payroll requirements including construction, public sector, government contracting, manufacturing, union, and non-profit sectors.

07:57 EST Tilt Holdings expands contract with AIRO Brands for products in Massachusetts - TILT Holdings announced the expansion of its partnership with Airo Brands, a multi-state consumer packaged goods company focused on proprietary inhalation products, beyond its current manufacturing and distribution agreement in Pennsylvania to include Massachusetts. An early client of TILT's subsidiary Jupiter Research, since 2016, Airo also licenses exclusive Jupiter products and collaborates on proprietary inhalation technologies AIRO products are currently available in Massachusetts as the company transitions to TILT subsidiary, Commonwealth Alternative Care to take over production and distribution. A leader in the cannabis inhalation space, AIRO is one of the top-selling brands in several markets including Nevada, Colorado, Illinois, Maryland and Washington. Airo is available in more than 1,250 dispensaries across the United States and Puerto Rico. Through this expanded partnership, TILT will distribute popular AIRO products including the AIROPr, AIROSport, and AIROX featuring formulations from AIRO's Strain Series, Artisan Series, and Live Flower Series, plus additional products throughout the year.

07:56 EST Sypris Solutions sees FY21 revenue growth of 20-25%, down from prior view - "We have updated our outlook to include a 20-25% growth in the Company's top line in 2021, which is down from our previous guidance. Gross margin is forecast to expand in the fourth quarter 400-500 basis points over the comparable period in 2020, which is expected to contribute to strong double-digit percentage growth in cash flow generated from operations for the full year.

07:54 EST Hostess Brands announces Chief Financial Officer departure - Last night, along with reporting financial results for the three months ended September 30, Hostess Brands also announced that Brian Purcell, Executive Vice President, Chief Financial Officer, resigned from the company, effective November 9, and that the company's board of directors has appointed Michael Gernigin, the company's Senior Vice President and Corporate Controller, as the company's Chief Accounting Officer and Interim CFO until a permanent successor has been named. "We appreciate Brian's contributions to Hostess and wish him the best in his future endeavors. Mike, who has been with the company since 2016, is a strong finance and accounting executive and is well positioned to lead the talented finance organization while we search for a new permanent CFO," commented Andy Callahan, the company's President and CEO.

07:53 EST Atlantica Sustainable Infrastructure sees 2021 CAFD $220M-$240M - Atlantica expects to close the year 2021 with a CAFD in the range of the guidance provided in March 2021, which is between $220 million and $240 million. The Company expects to achieve an Adjusted EBITDA including unconsolidated affiliates at or slightly below the low end of its guidance, which was $820 million, mainly due to the accounting adjustment to revenue caused by high electricity market prices in Spain. The accounting adjustment would not have a cash impact in 2021.

07:48 EST Monte Rosa Therapeutics expects cash to fund operations into late 2024 - Cash and cash equivalents as of Sept. 30, 2021, were $367.0 million, compared to $41.7 million as of December 31, 2020. The company expects its cash and cash equivalents, including the aggregate net proceeds from the initial public offering, will be sufficient to fund planned operations and capital expenditures into late 2024.

07:47 EST Kaleido Biosciences to appoint Alison Long as Chief Medical Officer - Kaleido Biosciences (KLDO) announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021. In her new role, Dr. Long will be responsible for leading the development of Kaleido's ongoing and future clinical programs, including the development of KB295 and KB109 in ulcerative colitis and chronic obstructive pulmonary disease, respectively. Dr. Long most recently served as interim Chief Medical Officer and Senior Vice President, Head of Clinical Development at Freeline Therapeutics (FRLN), and was responsible for the clinical development, clinical operations, medical affairs, and regulatory functions of Freeline's development programs.

07:46 EST Wave Life Sciences expects cash to fund requirements into 2Q23 - As of September 30, 2021, Wave had $123.9 million in cash and cash equivalents as compared to $184.5 million as of December 31, 2020. The decrease in cash and cash equivalents was mainly due to Wave's year-to-date net loss of $87.5 million, partially offset by the receipt of $21.2 million in proceeds under Wave's ATM equity program through September 30, 2021. Subsequently, in October 2021 Wave received an additional $52.1 million in cash, including $22.5 million from Takeda under the terms of the amendment to Wave's collaboration agreement with Takeda, and $29.6 million in proceeds under its ATM equity program from a block sale of ordinary shares based on interest received from new and existing shareholders following its Analyst and Investor Research Webcast in September 2021.

07:45 EST Century Therapeutics announces upcoming milestones - Pre-clinical data from the Company's CNTY-101 program and CAR-iT platform to be presented in two posters at the upcoming American Society of Hematology Annual Meeting and Exposition on December 11-14, 2021 in Atlanta, Georgia, and virtually; Virtual research and development update to be held on Thursday, December 16, 2021 from 8:00-9:30 AM EST. Century's management team will discuss an update on the Company's iPSC technology platform and pipeline.; Current Good Manufacturing Practice manufacturing facility expected to be operational in early 2022; and CNTY-101 IND filing remains on track for mid-2022.

07:43 EST Presto to become public through Ventoux CCM Acquisition Corp. merger agreement - Presto and Ventoux CCM Acquisition Corp. announced that they have entered into a definitive merger agreement that will result in Presto becoming a publicly listed company. The transaction values the combined company at an estimated pro forma equity value of approximately $1B. Upon closing, the company will be renamed Presto Technologies and expects to list its common stock on Nasdaq. The company will continue to be led by founder and CEO Rajat Suri and CFO Ashish Gupta. The board of directors will be chaired by longtime investor Krishna Gupta of REMUS Capital. Pursuant to the business combination, Ventoux will acquire the company through a reverse merger. The business combination values the company at approximately $1.04B pro forma equity value, at $10.00 per share. The transaction will be funded by cash from the Ventoux trust account of approximately $172.5M, assuming no redemptions by Ventoux's stockholders, and $70M of gross proceeds from the issuance of equity and convertible financings in the PIPE transaction. Following the transaction and after the payment of transaction expenses, the company is expected to add over $223.3M of cash to its balance sheet, assuming no redemptions. Assuming no redemptions of Ventoux's shares, the current holders of the company's securities will hold approximately 77% of the issued and outstanding shares of common stock immediately following the close of the transaction. The boards of directors of both the company and Ventoux have unanimously approved the proposed business combination, which is expected to be completed in the first half of 2022, subject to, among other things, the approval by Ventoux's stockholders, satisfaction of the conditions stated in the definitive agreement, including regulatory approvals, and other customary closing conditions, including a registration statement being declared effective by the U.S. Securities and Exchange Commission.

07:39 EST Finch Therapeutics announces upcoming milestones - Initiation of AUSPIRE Phase 1b trial of FIN-211 in children with ASD and GI symptoms anticipated in the first half of 2022, with an interim readout expected from the dose escalation portion of the trial in the second half of 2022 and topline data from the expansion cohort expected in 2023; Initiation of RECLAIM Phase 1b trial of CP101 in chronic HBV infection anticipated in early 2022, with topline data from an initial cohort expected in the second half of 2022; Topline data readout from PRISM4 Phase 3 trial of CP101 in recurrent CDI expected in the first half of 2023.

07:35 EST Halliburton signs Neftex Predictions agreement with Teck Resources - Halliburton (HAL) announced it signed an agreement with Teck Resources (TECK) to grant Teck access to Neftex Predictions to support their global mineral exploration efforts.

07:34 EST EU's General Court dismisses Google appeal, upholds EUR 2.4B fine - The European Union's General Court "largely dismisses" Google's action against the decision of the Commission finding that Google abused its dominant position by favoring its own comparison shopping service over competing comparison shopping services The General Court upholds the fine of EUR 2.42B imposed on Google. The court said: "First of all, the General Court considers that an undertaking's dominant position alone, even one on the scale of Google's, is not a ground of criticism of the undertaking concerned, even if it is planning to expand into a neighbouring market. However, the General Court finds that, by favouring its own comparison shopping service on its general results pages through more favourable display and positioning, while relegating the results from competing comparison services in those pages by means of ranking algorithms, Google departed from competition on the merits." Reference Link

07:33 EST Werewolf Therapeutics expects cash to fund operations through at least 2Q23 - As of September 30, 2021, cash and cash equivalents were $170.4 million, compared to $92.6 million as of December 31, 2020. The increase was primarily due to the receipt of $109.2 million in net proceeds from the initial public offering completed in May 2021, offset by operating expenses incurred during the period. Given the strength of its balance sheet, Werewolf expects its existing cash and cash equivalents to enable the funding of its operating expenses and capital expenditure requirements through at least the second quarter of 2023.

07:31 EST Hycroft Mining reports Q3 operating results - Reports production in Q3 of 14,831 ounces of gold and 91,437 ounces of silver represented a 240% and 295% increase in ounces produced, respectively, vs. 3Q20. As of the end of Q3, gold and silver production are approximately 91% and 75% of the mid-point of full year 2021 guidance. The company is discontinuing pre-commercial scale mining at its run-of-mine ("ROM") operation. CEO Diane Garrett said, "We are very disappointed that the challenges and economics for our pre-commercial scale ROM operation necessitates that we cease mining...We believe we are taking the most prudent approach to de-risking the project, including critical steps to continue the important work necessary for the development of this substantial mineral endowment. With respect to the technical study currently underway on the acid pressure oxidation process, we have run pit optimization work to analyze the in-pit value of the orebody under various processing options. The Acid POX process generates significantly higher relative economic value at Hycroft with substantial leverage to even modest increases in precious metals prices. We are extremely encouraged by the preliminary results we have seen on the Acid POX work to date and expect that the pre-feasibility study will highlight the significant value of Hycroft. I am very pleased with the progress we are making, thanks to the focus and diligence of our team and consulting partners as we complete these critical initiatives."

07:26 EST Aadi Bioscience expects cash to fund operations into 2024 - As of September 30, 2021, cash and cash equivalents totaled $161.4 million, an increase from $4.5 million as of December 31, 2020, resulting primarily from the consolidated capital and proceeds received from the PIPE financing. Based on our current plans, we expect cash and cash equivalents to fund operations into 2024.

07:17 EST Comscore expands partnership with American Spirit Media - Comscore announced an expanded partnership agreement with American Spirit Media to renew Comscore's Local currency services across its eight television markets. With this new agreement, Comscore will be providing currency measurement data and services, including Comscore's Advanced Automotive and Political segments, to all of ASM's television stations, which are located in Toledo OH, Jackson MS, Columbus GA, Wichita Falls & Lawton TX/OK, Lake Charles LA, and Wilmington NC.

07:16 EST iRobot teams with Amazon.com on voice-enabled intelligence for home robots - iRobot (IRBT) has teamed with Amazon (AMZN) to further advance voice-enabled intelligence for home robots that will result in more thoughtful, proactive smart home automations. As the first to enable robot vacuums to clean specific rooms by voice using Alexa, iRobot is combining the latest advances in navigation, object identification and artificial intelligence to bring smart home customers powerful capabilities to easily control where, when and how their robots clean.

07:14 EST Wendy's CEO says continues to grow breakfast business - "We are extremely proud of the progress we are making against our three strategic growth pillars," President and CEO Todd Penegor said. "We continued to grow our breakfast business, digital sales accelerated, and we meaningfully expanded our global footprint in the third quarter. Global Same-Restaurant sales grew in the high-single digits on a 2-year basis, reinforcing the strength of our brand in a challenging environment. Our focus on executing against our key priorities and our continued partnership with the best franchisees in the business give me confidence that we will achieve our vision of becoming the world's most thriving and beloved restaurant brand."

07:13 EST Zentalis expects cash to fund requirements into 3Q23 - As of September 30, 2021, Zentalis had cash, cash equivalents and marketable securities of $366.8 million. We believe that our existing cash, cash equivalents and marketable securities as of September 30, 2021 will be sufficient to fund our operating expenses and capital expenditures requirements into the third quarter of 2023.

07:07 EST Kymera Therapeutics announces upcoming expected milestones - IRAK4 Degrader Program: Presentation of data from the MAD portion of the Phase 1 trial in healthy volunteers, R&D Day, 12/16/21; Initiation of the Phase 1 patient cohort, including patients with hidradenitis suppurativa and atopic dermatitis in 1Q22; Presentation of Phase 1 data in AD and HS patient cohort in mid-2022. IRAKIMiD Degrader Program: Clearance of KT-413 IND application to allow for subsequent initiation of Phase 1 clinical trial in relapsed/refractory B cell lymphomas, including MYD88-mutant DLBCL in 4Q21; Presentation of additional KT-413 preclinical data and indication expansion strategies in 4Q21 and 1H22; Establish Phase 1 proof-of-mechanism in patients in 2022. STAT3 Degrader Program: Initiation of Phase 1 clinical trial of KT-333 in relapsed/refractory liquid and solid tumors in 4Q21; Establish Phase 1 proof-of-mechanism in patients in 2022.

07:04 EST Galera Therapeutics sees cash, cash equivalents funding operations into 2023 - As of September 30, 2021, Galera had cash, cash equivalents and short-term investments of $88.7M.

07:03 EST TScan Therapeutics announces expected milestones - Liquid Tumor Programs: TScan's two lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are designed to target HA-1 and HA-2, respectively, and treat patients with hematological malignancies who are undergoing allogeneic hematopoietic stem cell transplantation. TScan will present two posters related to TSC-100 and TSC-101 at the upcoming ASH Annual Meeting and Exposition. IND-enabling studies and the submission of IND applications to the U.S. Food and Drug Administration are planned for TSC-100 and TSC-101 during the fourth quarter 2021. Following the IND submissions and pending acceptance by the FDA, clinical trials for TSC-100 and TSC-101 are expected to begin in the first half of 2022 with preliminary data expected in the second half of 2022. Solid Tumor Programs: TScan's TSC-200 series of TCR-T therapy candidates include a combination of known targets, such as HPV16 for TSC-200, PRAME for TSC-203, and MAGE-A1 for TSC-204, as well as targets that are novel antigens for TCR-T therapy, such as those for TSC-201 and TSC-202. TScan plans to present preclinical data of the TSC-2xx series during the first half of 2022. TScan plans to progress IND-enabling studies for the TSC-2xx series and submit IND applications during the second half of 2022, including for TSC-200 for HPV, during the second half of 2022. Further INDs are planned for 2023. Infectious Disease Program Research is continuing into potential T cell-focused COVID-19 vaccine constructs utilizing TScan's novel T cell target discoveries.

07:02 EST Wendy's reports Q3 U.S. same-restaurant sales growth 2.1% - Reports Q3 International same-restaurant sales growth of 14.7%; global 3.3%.

06:51 EST Ault Global Holdings subsidiary BitNile enters into partnership with Bitmain - Ault Global Holdings' subsidiary, BitNile, has entered into a partnership with Bitmain, with the acquisition of Bitmain's first environmentally friendly S19XP Antminers. The S19XP Antminer is faster and requires less energy than do BitNile's current miners, providing approximately 40% more processing power while using approximately the same amount of power. BitNile is one of only five companies worldwide authorized to acquire and deploy this technology from Bitmain The company intends to provide the expected delivery schedule of the new S19XP Antminers and an update on its revenue forecast for 2022 and 2023 on or about December 20, 2021.

06:43 EST Magna-s Normal Course Issuer Bid accepted by Toronto Stock Exchange - Magna's Notice of Intention to Make a Normal Course Issuer Bid has been accepted by the Toronto Stock Exchange. Pursuant to the Notice, Magna may purchase up to 29,948,000 Magna Common Shares, representing approximately 10% of its public float. As at November 1, 2021, Magna had 300,752,976 issued and outstanding Common Shares, including a public float of 299,481,694 Common Shares. The Bid will commence on November 15, 2021 and will terminate no later than November 14, 2022. Magna's current normal course issuer bid announced in November 2020 for the purchase of up to 29,623,300 Common Shares will expire on November 14, 2021. As at the close of trading on November 1, 2021, Magna has purchased 2,903,523 Common Shares at a weighted-average price of $91.52.

06:39 EST KalVista provides update on clinical trial progress for KVD900 - KalVista Pharmaceuticals provided an update on the clinical trial progress for KVD900 in development for oral on-demand treatment of hereditary angioedema. "We had a productive End-of-Phase 2 meeting with the FDA and recently received meeting minutes which confirmed that our Phase 3 trial design, similar to our recent successful Phase 2 trial, is expected to be appropriate to support an NDA submission," said Andrew Crockett, CEO of KalVista. "Our development team is finalizing the Phase 3 trial protocol and preparing for study initiation, and we anticipate patients will be dosed during the first quarter of 2022. KalVista is well-capitalized, with funding until at least early 2024, which we expect takes us beyond data from both this Phase 3 trial and the ongoing Phase 2 trial of KVD824." The Phase 3 clinical trial of KVD900 is a crossover design evaluating dose levels of 300 mg and 600 mg KVD900 against placebo. The primary endpoint of this Phase 3 trial is time to beginning of symptom relief. The trial is expected to be conducted at more than 50 sites worldwide and recruit approximately 100 patients, consistent with late stage trials of approved on-demand treatments for HAE. The trial is intended to evaluate all HAE attacks, including laryngeal attacks and breakthrough attacks for patients using prophylaxis. Similar to the Phase 2 trial for which positive data was announced earlier in 2021, patients will administer treatment as soon as they recognize the onset of an attack. More details will be forthcoming when the trial initiates.

06:14 EST Landsea Homes identifies 'additional material weaknesses' - The company stated, "As previously disclosed, management concluded that the company had a material weakness as of December 31, 2020 relating to the company's internal controls over financial reporting with respect to accounting for warrants that we are currently working to remediate. As an 'emerging growth company' we are not currently required to comply with the SEC rules that implement Section 404 of the Sarbanes-Oxley Act, and are therefore not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose; however, in anticipation of becoming subject to the SEC rules that implement Section 404 of the Sarbanes-Oxley Act by year-end, we have been working to enhance our internal control framework and in doing so, have identified additional material weaknesses relating to an insufficient complement of resources with an appropriate level of expertise, knowledge and training and inadequate documentation of controls commensurate with the financial reporting requirements for an SEC registrant. As management continues to evaluate their internal control environment in preparation for compliance with Section 404 of the Sarbanes-Oxley requirements, additional material weaknesses may be identified."

06:06 EST BioRestorative Therapies names Robert Kristal as CFO - BioRestorative Therapies announced that it has appointed Robert Kristal to the position of CFO. Kristal brings an extensive array of strategic and financial markets experience to the company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Most recently he served as the Head of Research for H.C. Wainwright, growing their research product and presence in the biotech/biopharma space.

05:39 EST Fiverr reports Q3 EPS 21c, consensus (1c) - Reports Q3 revenue $74.32M, consensus $71.1M. Active buyers as of September 30 grew to 4.1M, compared to 3.1M as of September 30, 2020, an increase of 33% year over year. Spend per buyer as of September 30 reached $234, compared to $195 as of September 30, 2020, an increase of 20% year over year. Take rate for the quarter ended September 30 was 28.4%, up from 27.0% for the quarter ended September 30, 2020, an increase of 140 basis points year over year. "Fiverr delivered a strong third quarter as we saw revenue growth of 42% y/y. We are also making exciting progress towards our long-term vision of the future of work with the acquisitions of CreativeLive and Stoke Talent, further strengthening our value proposition to increase market share in our massive TAM," said Micha Kaufman, Fiverr's founder and CEO, "I'm also thrilled to announce the launch of our new brand campaign, which deeply resonates with me and underscores our belief that anyone should have access to opportunities to pursue their dreams."

05:28 EST Erytech Pharma publishes Erycaps study data in Acta Pharmaceutica Sinica B - Erytech Pharma announced the publication of a multiparametric characterization of red blood cells after its proprietary technology Erycaps in the journal Acta Pharmaceutica Sinica B. The aim of the study was to evaluate the impact of hypotonic dialysis using Erycaps encapsulation process on RBCs physiology and integrity, to ensure they can properly achieve their function as drug carriers. Hematological parameters, morphology, proteomic and metabolomic profiles, deformability, lesion markers as well as in vivo biodistribution in a mouse model, were assessed. These parameters were compared between processed RBCs loaded with L-asparaginase, processed RBCs without drug and non-processed RBCs. This multiparametric study was performed in collaboration with academic experts having different expertise in RBC field. In conclusion, a full and in-depth characterization of the physiological, biophysical, metabolomic, proteomic and cellular properties of RBCs after drug loading was performed. This wide characterization allowed to have a systemic and integrative approach to demonstrate that Erycaps hypotonic dialysis encapsulation process induces some changes to RBCs features without substantially affecting their survival or their capacity to carry therapeutics making them suitable as drug carriers.

05:23 EST L&T Technology Services, Microsoft partner to offer smart manufacturing solution - L&T Technology Services (LTTS) announced that it has entered into an agreement with Microsoft (MSFT) to offer LTTS' Energy & Sustainability Manager Solution on Microsoft Azure to transform and create sustainable factories of the future. This latest agreement is part of LTTS' expanded collaboration with Microsoft to enable enterprises to leverage LTTS' Manufacturing Solution suite hosted on Azure enterprise cloud-first, mobile-first infrastructure.

05:15 EST Willis Towers Watson, Indeez announce joint broking partnership in APAC - Willis Towers Watson and European insurtech, Indeez, announced a joint broking partnership to distribute insurance products for independent workers working with digital platforms in Asia Pacific. Through this partnership, Indeez will leverage the local market network and relationships of Willis Towers Watson in Asia Pacific to build tailored protection and benefits programs for the community of gig workers in the region.

05:11 EST NXP Semiconductors, Ford collaborate on car experiences and services - NXP Semiconductors (NXPI) announced a collaboration with the Ford (F) to deliver driver experiences, convenience and services across its global fleet of vehicles, including the 2021 Ford F-150 pickup, Mustang Mach-E and Bronco SUVs. Ford's new fully networked vehicle architecture implements NXP's vehicle networking processors and the i.MX 8 Series processors, working together to upgrade vehicles. NXP's vehicle network processors provide in-vehicle networking and enable the gateway to rapidly deploy over-the-air, or OTA, software updates and new services, while processing and sending vehicle data to the cloud. The NXP i.MX 8 Series processors help enable Ford SYNC4 to deliver multimedia user experiences enabling in-car productivity, cloud services, enhanced voice recognition, and location-based applications.

04:47 EST MEI Pharma granted orphan status for lymphoma treatment - The FDA granted MEI Pharma orphan status for its treatment of follicular lymphoma Zandelisib. Reference Link